Conditions: Melanoma
Keywords: Pembrolizumab Intratumoral pIL-12 Electroporation Tumor-infiltrating lymphocyte melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: no

Brief summary:
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ "exhausted" lymphocytes in the tumor. Part B will enroll patients who have or are failing pembrolizumab at least 12 weeks after starting Programmed cell death protein 1 (PD-1) antibody alone or in combination, or, who have been selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ "exhausted" lymphocytes in the tumor.

Detailed description:
Closed to enrollment earlier than expected due to high response rate in order to advance to phase 2b in proven PD-1-refractory patients. A total of 24 patients were consented instead of the planned enrollment of 42 patients.

Arms:
arm 1: Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle

Interventions: intervention 1: Pembrolizumab intervention 2: pIL-12
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_SAP_000.pdf: 
AN OPEN-LABEL, PHASE II, MULTICENTER STUDY OF ENHANCING 
PEMBROLIZUMAB RESPONSES IN MELANOMA THROUGH INTRATUMORAL PIL- 
12 ELECTROPORATION 
PROTOCOL NUMBER: CC #15852 
STUDY DRUG: PEMBROLIZUMAB (MK-3475) AND PIL-12 ELECTROPORATION
VERSION NUMBER: 4.0 
VERSION DATE: September 06, 2018 
IND NUMBER: 16353 
Principal Investigator (Sponsor-Principal Investigator) 
Katy Tsai, MD 
University of California San Francisco 
 San Francisco, CA 94158 
 
 
 
Co-Investigators 
Robert Andtbacka, MD 
Huntsman Cancer Institute, University of Utah 
Salt Lake City, UT 84112 
Statistician 
Jimmy Hwang, PhD 
University of California, San Francisco 
NCT ID: NCT02493361


IT-pIL12-EP and anti-PD-1
Page 2
Revision History 
Version 1.0 
10-09-2014
Version 1.1 
03-13-2015
Version 1.2 
04-20-2015
Version 2.0 
06-02-2015
Version 2.1 
10-16-2015
Version 3.0 
04-04-2017
Version 3.1 
10-12-2017
Version 4.0 
09-06-2018
Proprietary and Confidential 
The information in this document is considered privileged and confidential, and may not be disclosed to others except 
to the extent necessary to obtain Institutional Review Board approval and informed consent, or as required by Federal 
and State laws.  Persons to whom this information is disclosed should be informed that this information is privileged 
and confidential and that it should not be further disclosed. 


IT-pIL12-EP and anti-PD-1
Page 3
PROTOCOL SIGNATURE PAGE 
Protocol No.: 15852 
Version Date: 09-06-2018 
1. I agree to follow this protocol version as approved by the UCSF Protocol Review Committee
(PRC), UCSF Institutional Review Board (UCSF IRB), and Data Safety Monitoring Committee
(DSMC).
2. I will conduct the study  in  accordance  with  applicable  UCSF IRB,  Federal regulations, and
state and local laws to maintain the protection of  the rights and welfare of study participants.
3. I certify that I, and the study staff, have received the requisite training to conduct this research
protocol.
4. I have read and understand the information in the Investigators’ Brochure (or Manufacturer’s
Brochure) regarding the risks and potential benefits. I agree to conduct the protocol in
accordance with Good Clinical Practices (ICH-GCP), the applicable ethical principles, the
Statement of Investigator (Form FDA 1572), and with local regulatory requirements.  In
accordance with the FDA Modernization Act, I will ensure the registration of the trial on the
www.clinicaltrials.gov website.
5. I agree to maintain adequate and accurate records in accordance with UCSF IRB policies,
Federal, state and local laws and regulations.
UCSF Principal Investigator / Study Chair 
Printed Name 
Signature 
Date 
Principal Investigator 
Site name and address 
Printed Name 
Signature 
Date 


Version date: 09-06-2018
Protocol CC#:15852
ABSTRACT
IT-pIL12-EP and anti-PD-1
Page 4
 
 
 
Title 
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab 
Responses in Melanoma through Intratumoral pIL-12 Electroporation 
Patient 
population 
Patients with melanoma with progressive locally advanced or metastatic 
disease that is not amenable to definitive local therapy with curative intent. 
Rationale for 
Study 
Inhibition of the PD-L1/PD-1 axis with mAbs is transforming the therapeutic 
landscape in melanoma, with objective response rates (ORR) in the range of 
20-50%. Unfortunately, even in melanoma, which is considered to be one of 
the most immunoresponsive types of solid tumor, the majority of patients will 
not respond to monotherapy with anti-PD-1 agents. These primary PD-1 
nonresponders represent a significant unmet medical need that may benefit 
from a combination therapy tailored to the negative PD-L1 nonresponder 
phenotype. Combining the anti-PD-1 agent, pembrolizumab, with an agent 
capable of driving an effective T cell response, such as IL-12, may increase 
the immunogenicity and CTL activity in the nonresponder phenotype and 
enhance response to pembrolizumab. 
Primary 
Objective 
To assess the anti-tumor efficacy (defined as the best overall response rate 
using RECIST v1.1) of the combination of intratumoral pIL-12 EP and 
pembrolizumab in patients with melanoma who are progressing or have 
progressed on anti-PD-1 therapy. 
Secondary 
Objectives 
To assess safety and tolerability of the combination of intratumoral pIL-12 EP 
and pembrolizumab; duration of response; twenty-four week landmark 
progression free survival; median progression free survival; overall survival; 
and best overall objective response rate by  immune-related Response 
Criteria (irRC) in melanoma patients treated with the combination of 
intratumoral pIL-12 EP and pembrolizumab. 
Study Design 
This is a multi-center, Phase II, open label, single-arm trial of intratumoral pIL- 
12 EP in combination with pembrolizumab in patients with melanoma. 
Patients will initiate treatment with pembrolizumab concurrently with the first 
cycle of intratumoral pIL-12 EP. Pembrolizumab will be administered at 200 
mg flat dose every 3 weeks. Cycles of intratumoral pIL-12 EP (each cycle 
consisting of treatment on days 1, 5 and 8) will occur every 6 weeks as long 
as patients have accessible lesions for EP. Patients will be evaluated for 
response every 12 weeks by RECIST v1.1.  Patients will continue on therapy 
if they have stable disease or better, defined under investigator evaluation at 
the time of disease evaluations. Therapy will be given until disease 
progression or unacceptable toxicity. The only exception will be those patients 
who experience a confirmed CR and who have been on treatment for at least 
6 months; these patients may discontinue treatment at the investigator’s 
discretion. Patients may reinitiate either therapy post- complete remission 
relapse if the study remains open and the patient meets the conditions 
outlined in the protocol. Patients will be followed continually for safety and 
tolerability by assessment of adverse events. 
Number of 
patients 
42 evaluable patients 
 
 
 


IT-pIL12-EP and anti-PD-1
Page 5
Version date: 10-12-2017
Protocol CC#:15852
Duration of 
Therapy 
Patients may continue treatment for as long as they continue to benefit from 
treatment for up to 2 years or until disease progression; inter-current illness 
that prevents further administration of treatment; unacceptable adverse 
event(s); patient decision to withdraw from the study; significant patient non- 
compliance  with  protocol;  general or  specific changes in the patients’ 
condition that render the patient unacceptable for further treatment in the 
judgment of the investigator; or those who experience a confirmed CR from 
the time of study entry. After 24 months, patients may continue study 
treatment if approved by the Principal Investigator, OncoSec Medical, and 
Merck. Patients may reinitiate either therapy post-complete remission relapse 
if the study remains open and the patient meets the conditions outlined in the 
protocol. 
Duration of 
Follow up 
After the end of treatment, each subject will be followed for 30 days for 
adverse event monitoring (serious adverse events will be collected for 90 
days after the end of treatment as described in Section 7). For subjects who 
discontinue for reasons other than progressive disease, every attempt should 
be made to continue monitoring their disease status by radiologic imaging. 
Monitoring should continue (1) until start of a new anti-cancer treatment, (2) 
until documented disease progression, or (3) until death, whichever occurs 
first. Radiographic imaging in follow-up may be performed as clinically 
indicated or per local standard of care. Each subject will be followed for 
overall survival until death, withdrawal of consent, or the end of the study, 
whichever occurs first. 
Duration of 
study 
The study is expected to reach completion ~24 months from the time the 
study opens to accrual. However, the study duration will depend on the rate of 
patient enrollment. 
Study Drugs 
Each treatment cycle is 3 weeks. 
Plasmid interleukin-12 (pIL-12) for intratumoral injection at ¼ tumor volume at 
concentration of 0.5 mg/mL followed by in vivo electroporation (EP) of six 
pulses at field strengths (E+) of 1500 V/cm and pulse width of 100 μs at 1- 
second intervals. A minimum of 0.1 mL pIL-12 per lesion for lesions <0.1 cm3 
will be administered. Intratumoral pIL-12 EP will be administered on Days 1, 5 
and 8 of every odd cycle (every 6 weeks). 
Pembrolizumab is a humanized mAb administered intravenously at 200 mg 
every 3 weeks. 
Safety 
Assessments 
Safety will be assessed during the study by documentation of adverse events 
(AEs), clinical laboratory tests, physical examination, vital sign 
measurements, and Eastern Cooperative Oncology Group (ECOG) 
performance status. Toxicities will be defined and graded using NCI CTCAE 
4.0. 
Efficacy 
Assessments 
Overall response rate (ORR) will be evaluated using RECIST v1.1 by 
investigator evaluation at each re-staging assessment performed 
approximately every 12 weeks. An independent central review may also be 
employed for response evaluations. Duration of response (DOR), twenty-four 
week landmark progression free survival (PFS@24), median progression free 
survival (PFS), overall survival (OS) and ORR evaluated by immune related- 
Response Criteria (irRC) will also be assessed. 


IT-pIL12-EP and anti-PD-1
Page 6
Version date: 10-12-2017
Protocol CC#:15852
Unique Aspects 
of this Study
This is the first study to:
1.
Evaluate the safety and efficacy of pIL-12 EP and any anti PD-1/PD- 
L1 inhibitor, including pembrolizumab.
2.
Investigate the combination of a pembrolizumab and an interleukin,
namely IL-12.
3.
Understand the biology of transforming tumors treated with IL-12 and
pembrolizumab.
4.
Delineate the biology of intratumoral immune response of a PD-1
inhibitor and IL-12.
LIST OF ABBREVIATIONS 
ADCC 
antibody-dependent cell- mediated cytotoxicity 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ANC 
absolute neutrophil count 
ASL 
accessible superficial lesion 
AST 
aspartate aminotransferase 
BUN 
blood urea nitrogen 
CBC 
complete blood cell (count) 
CDC 
complement-dependent cytotoxicity 
CR 
complete response 
CRC 
Clinical Research Coordinator 
CRF 
case report form 
CT 
computerized tomography 
CTL 
Cytotoxic T-lymphocytes 
CTCEA 
Common Terminology Criteria for Adverse Events 
CTEP 
Cancer Therapy Evaluation Program 
CTMS 
Clinical Trial Management System 
DFS 
disease-free survival 
DLT 
dose limiting toxicity 
DSMC 
Data and Safety Monitoring Committee 
DSMP 
Data and Safety Monitoring Plan 
ECOG 
Eastern Cooperative Oncology Group 
EOS 
End of Study 
EP 
Electroporation 
FCBP 
female of childbearing potential 


IT-pIL12-EP and anti-PD-1
Page 7
Version date: 10-12-2017
Protocol CC#:15852
FDA 
Food and Drug Administration 


IT-pIL12-EP and anti-PD-1
Page 8
Version date: 10-12-2017
Protocol CC#:15852
GCP 
Good Clinical Practice 
HBeAg 
Hepatitis B “e” antigen 
HBV 
hepatitis B virus 
HCT 
Hematocrit 
HCV 
hepatitis C virus 
HDFCCC 
Helen Diller Family Comprehensive Cancer Center 
HGB 
Hemoglobin 
HIV 
human immunodeficiency virus 
ICH 
International Conference on Harmonization 
IDO 
Indoleamine 2,3-dioxygenase 
IND 
investigational new drug application 
IL 
interleukin 
irAEs 
Immune-related adverse events 
IRB 
Institutional Review Board 
irRC 
immune-related Response Criteria 
IT-pIL-12 EP 
intratumoral plasmid IL-12 electroporated 
IT 
Intratumoral 
IV 
Intravenous 
LDH 
Lactate dehydrogenase 
mAb 
Monoclonal antibody 
MedDRA 
Medical Dictionary for Regulatory Activities 
MRI 
Magnetic resonance imaging 
NCI 
National Cancer Institute 
ORR 
Overall response rate 
pDC 
Progrenitor dendritic cells 
PD 
Disease progression 
pIL-12 
Plasmid interleukin-12 
PK 
Pharmacokinetics 
PR 
Partial response 
PRC 
Protocol Review Committee (UCSF) 
RBC 
Red blood cell (count) 
SD 
Stable disease 
SD 
Standard deviation 
SGOT 
Serum glutamic oxaloacetic transaminase 
SGPT 
Serum glutamic pyruvic transaminase 
TIL 
Tumor infiltrating lymphocytes 
TKI 
Targeted kinase inhibitors 
ULN 
Upper limit of normal 
WBC 
White blood cell (count) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 8
 
 
 
CONTENTS 
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma   
through Intratumoral pIL-12 Electroporation .............................................................................................................................1 
Protocol Number: CC #15852 .........................................................................................................................................................1 
Study Drug: Pembrolizumab (MK-3475) and pIL-12 electroporation .........................................................................1 
Version Number: 3.0 ......................................................................................................................................................................1 
Version Date: ......................................................................................................................................................................................1 
IND Number: 16353 ............................................................................................................................................................................1 
Protocol Signature Page ..........................................................................................................................................................................3 
Abstract ..........................................................................................................................................................................................................4 
List of Abbreviations ................................................................................................................................................................................6 
1 Introduction ........................................................................................................................................................................................12 
1.1 
Background on Indication .....................................................................................................................................................12 
1.2 
Background on the Compounds ......................................................................................................................................12 
1.3 
Rationale for the Proposed Study ...................................................................................................................................16 
1.4 
Correlative Studies ................................................................................................................................................................17 
1.4.1 Biomarkers ..............................................................................................................................................................................17 
1.4.2 Future Biomedical Research .......................................................................................................................................18 
2 Objectives of the Study ...................................................................................................................................................................18 
2.1 
Primary .......................................................................................................................................................................................18 
2.2 
Secondary ..................................................................................................................................................................................18 
2.3 
Exploratory Objectives, Other Assessments ..............................................................................................................18 
2.4 
Endpoints ...................................................................................................................................................................................19 
2.4.1 Primary Endpoints ...........................................................................................................................................................19 
2.4.2 Secondary Endpoints ...........................................................................................................................................................19 
2.4.3 Exploratory Endpoints ........................................................................................................................................................19 
3 Study Design ........................................................................................................................................................................................20 
3.1 
Characteristics .........................................................................................................................................................................20 
3.2 
Number of Subjects ...............................................................................................................................................................20 
3.3 
Eligibility Criteria ...................................................................................................................................................................20 
3.3.1 Inclusion Criteria ..............................................................................................................................................................21 
3.3.2 Exclusion Criteria .............................................................................................................................................................22 
3.4 
Duration of Therapy .............................................................................................................................................................23 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 9
3.5 
Duration of Follow Up ......................................................................................................................................................24 
3.6 
Randomization Procedures ...............................................................................................................................................24 
3.7 
Study Timeline ........................................................................................................................................................................25 
3.7.1 Primary Completion ............................................................................................................................................................25 
3.7.2 Study Completion .............................................................................................................................................................25 
4 Study Drugs .....................................................................................................................................................................................26 
4.1 
Description, Supply and Storage of Investigational Drugs ..................................................................................26 
4.1.1 Plasmid Interleukin-12 (pIL-12) ...............................................................................................................................26 
4.1.2 Pembrolizumab .................................................................................................................................................................27 
4.2 
Drug Accountability ...........................................................................................................................................................28 
4.3 
Drug Ordering .......................................................................................................................................................................28 
4.4 
Packaging and Labeling of Study Drugs ....................................................................................................................28 
4.5 
Clinical Supplies Disclosure ............................................................................................................................................28 
4.6 
Returns and Reconciliation ................................................................................................................................................28 
5 
Treatment Plan ..................................................................................................................................................................................30 
5.1 
Dosage and Administration ............................................................................................................................................30 
5.1.1 Timing of Dose Administration ..................................................................................................................................30 
5.1.2 Post-complete Remission Relapse Administration .............................................................................................31 
5.1.3 Other Modality(ies) or Procedures ..........................................................................................................................32 
5.2 
Dose Modifications and Dosing Delays ........................................................................................................................33 
5.3 
Monitoring and Toxicity Management .........................................................................................................................35 
5.4 
Rescue Medications & Supportive Care .......................................................................................................................35 
5.4.1 Supportive Care Guidelines .........................................................................................................................................35 
6 Study Procedures and Observations ........................................................................................................................................39 
6.1 
Schedule of Procedures and Observations .................................................................................................................39 
6.1.1 Pretreatment Period .......................................................................................................................................................39 
6.1.2 Treatment Period .............................................................................................................................................................41 
6.1.3 Safety Follow-Up/End of Study Visit Study Procedures .................................................................................43 
6.1.4 Post-treatment/Survival Follow-up Procedures .................................................................................................44 
6.1.5 Discontinuation of Therapy .........................................................................................................................................45 
6.1.6 Withdrawal/Discontinuation .........................................................................................................................................45 
6.1.7 Criteria for Pain Assessment for AE reporting ...................................................................................................50 
6.2 
Guidelines for Biopsy Collection .....................................................................................................................................50 
6.3 
Concomitant Medications/Vaccinations (allowed & prohibited) ....................................................................51 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 
6.3.1 Acceptable Concomitant Medications .....................................................................................................................51 
6.3.2 Prohibited Concomitant Medications .....................................................................................................................51 
6.4 
Dietary Restrictions ..............................................................................................................................................................52 
6.5 
Contraception ..........................................................................................................................................................................52 
6.5.1 Use in Pregnancy ..............................................................................................................................................................53 
6.5.2 Use in Nursing Women ..................................................................................................................................................53 
7 Reporting and Documentation of Results .................................................................................................................................54 
7.1 
Evaluation of Efficacy (or Activity) ................................................................................................................................54 
7.1.1 Antitumor Effect – Solid Tumors ...............................................................................................................................54 
7.2 
Evaluation of Safety ...........................................................................................................................................................58 
7.2.1 Evaluating Adverse Events ..........................................................................................................................................58 
7.2.2 Events of Clinical Interest .............................................................................................................................................60 
7.3 
Recording of an Adverse Event .......................................................................................................................................60 
7.4 
Follow-up of Adverse Events ............................................................................................................................................61 
7.5 
Adverse Events Monitoring ...............................................................................................................................................62 
7.6 
Expedited Reporting .............................................................................................................................................................62 
8 Statistical Considerations and Evaluation of Results .........................................................................................................66 
8.1 
Study Endpoints ..........................................................................................................................................................................66 
8.1.1 Primary Endpoint .............................................................................................................................................................66 
8.1.2 Secondary Endpoints ......................................................................................................................................................66 
8.1.3 Exploratory Endpoints ......................................................................................................................................................66 
8.1.4 Study Design .......................................................................................................................................................................66 
8.1.5 Sample Size and Power Estimate ..............................................................................................................................67 
8.1.6 Replacement Policy .........................................................................................................................................................67 
8.1.7 Accrual estimates .................................................................................................................................................................67 
8.2 
Analyses Plans .............................................................................................................................................................................67 
8.2.1 Analysis Population .........................................................................................................................................................67 
Safety Analysis Sets ...........................................................................................................................................................................68 
8.3 
Evaluation of Safety ..............................................................................................................................................................68 
8.4 
Interim Analysis and Stopping Rules ............................................................................................................................68 
8.5 
Clinical Criteria for Early Trial Termination .............................................................................................................68 
9 Study Management ...........................................................................................................................................................................70 
9.1 
Pre-study Documentation ..................................................................................................................................................70 
9.2 
Institutional Review Board Approval ...........................................................................................................................70 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 
9.3 Informed Consent ..................................................................................................................................................................70 
9.4 Changes in the Protocol ......................................................................................................................................................71 
9.5 Handling and Documentation of Clinical Supplies ....................................................................................................71 
9.6 Case Report Forms (CRFs) .................................................................................................................................................71 
9.7 Oversight and Monitoring Plan ...........................................................................................................................................72 
9.8 Multicenter communication ..............................................................................................................................................72 
9.9 Record Keeping and Record Retention ........................................................................................................................73 
9.10 Coordinating Center Documentation of Distribution .......................................................................................73 
9.11 Study Personnel Training Plan .......................................................................................................................................73 
10 Protection of Human Subjects ....................................................................................................................................................75 
10.1 Protection from Unnecessary Harm .........................................................................................................................75 
10.2 Protection of Privacy .......................................................................................................................................................75 
References .......................................................................................................................................................................................................76 
Appendices .................................................................................................................................................................................................79 
APPENDIX 1 Performance Status Criteria ..............................................................................................................................79 
APPENDIX 2 Data and Safety Monitoring Plan for Multicenter Institutional Study ............................................80 
(Phase 2 or 3 Institutional Study) ..............................................................................................................................................80 
APPENDIX 3 UCSF Policy/Procedure for Required Regulatory Documents for a UCSF Multicenter 
Investigator-Initiated Oncology Clinical Trials with an Investigator held Investigational New Drug (IND) 
................................................................................................................................................................................................................. 82 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 12
 
 
 
1 INTRODUCTION 
1.1 BACKGROUND ON INDICATION 
Melanoma is one of the most dangerous forms of skin cancer and one of the seven most common cancers 
in the United States.  Furthermore, its incidence is increasing [1]. When melanoma is caught early 
enough, surgical excision can be curative in the majority of Stage I and II melanomas and the overall 5- 
year survival rate for patients without spread to regional lymph nodes or other organs is about 98 
percent in the United States [2]. At later stages, malignant melanoma remains a deadly and frequently 
difficult to treat cancer. The overall 5-year survival rate for patients falls to 62 percent when the disease 
reaches the lymph nodes and 15 percent when the disease metastasizes to distant organs [2]. 
Numerous chemotherapy regimens have been tested in melanoma with only modest success and limited 
overall survival benefit. Targeted kinase inhibitors (TKI) such as BRAF and MEK signal transduction 
inhibitors either alone or in combination, and immunotherapy agents such as the CTLA4 inhibitor 
ipilimumab are current first-line options in the metastatic setting, each of which have proven benefits. 
While BRAF and/or MEK inhibitors are very effective in terms of producing initial responses for 
approximately 50% of biomarker-positive patients, most patients will progress within 6 months and few 
patients have lasting responses [33]. Furthermore, the variable mechanisms of resistance to TKIs have 
limited the determination of effective sequenced treatment algorithms. Early immunotherapy agents 
such as interferon and high-dose IL-2 were of limited efficacy in the metastatic setting and had extensive 
toxicity limiting their overall applicability and long-term use. While immunotherapy can be extremely 
effective it is not able to halt the very aggressive disease that is commonplace in melanoma and does not 
benefit the majority of patients. 
The importance of intact immune surveillance along with evidence demonstrating a correlation between 
tumor infiltrating lymphocytes (TILs) and favorable prognosis support continued efforts to focus on 
targeting pathways of T cell activation [34]. One major pathway emerging as a target for immunotherapy 
is the PD-1/PD-L1 axis due to the inhibition of T cell activation that is triggered through the T cell 
receptor upon binding of the PD-1 ligands (PD-L1 and PD-L2) to PD-13. Inhibition of the PD-1/PD-L1 axis 
by monoclonal antibodies (mAbs) continues to be investigated as it plays a critical role in tumor immune 
evasion. Additionally, the presence of CD8+ T cells and the ratio of CD8+ effector T cells/FoxP3+ 
regulatory T cells seems to correlate with improved prognosis and long-term survival in solid 
malignancies such as melanoma5,6; thus enhancing T cell response and increasing immunogenicity 
continue to be of therapeutic importance in treating solid tumors. 
 
1.2 BACKGROUND ON THE COMPOUNDS 
Preclinical in vitro and in vivo experiments have shown that PD-1 and/or PD-L1 blockade using 
monoclonal antibodies (mAb) enhances tumor-cell specific activation, cytokine production, anti- tumor 
effector mechanisms, and clearance of tumor cells by the immune system [7-12]. 
Murine pre-clinical studies have shown that administration of antibodies blocking PD-1/PD-L1 
interaction enhances infiltration of tumor-specific CD8+ T cells and leads ultimately to tumor rejection. 
The presence of IFN-γ, granzyme B, and perforin upon blockade of the PD-1 pathway indicate local 
infiltration and activation of effector T cell function in vivo [8-10, 11,13,14]. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 13
 
 
 
 
Pembrolizumab is a potent and highly selective humanized mAb of the IgG4/kappa isotype designed to 
directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pembrolizumab contains 
the S228P stabilizing mutation and has no antibody-dependent cell- mediated  cytotoxicity (ADCC) or 
complement-dependent cytotoxicity (CDC) activity. 
Pembrolizumab modulates the level of interleukin-2 (IL-2), tumor necrosis factor alpha (TNFα), 
interferon gamma (IFN-Υ), and other cytokines. The antibody potentiates existing immune responses 
only in the presence of antigen and does not nonspecifically activate T cells. Pembrolizumab strongly 
enhances T lymphocyte immune responses in cultured blood cells from healthy human donors, cancer 
patients, and primates. In T cell stimulation assays using human donor blood cells, the EC50 was in the 
range of 0.1 to 0.3 nM (see pembrolizumab Investigator Brochure). 
Pembrolizumab is currently undergoing Phase III testing in advanced melanoma and lung populations. 
Data from the Phase I/II melanoma trials demonstrate a high rate of sustained tumor regression, with 
mainly grade 1 or grade 2 toxic effects15. The functional activity of pembrolizumab measured in an ex   
vivo SEB-induced IL-2 production assay (modulation assay) in whole blood samples from 2 cynomolgus 
monkey studies was used to determine the starting dose in the Phase I dose escalation study. Increased 
production of cytokines such as IL-2 have been generally regarded as a marker of potential anti-tumor 
immune activity and blocking PD-1 was found to increase this IL-2 response. The ex vivo IL-2 modulation 
assay data indicated a potency (EC50) of approximately 15 μg/mL (90% CI, 5-36 μg/mL) for 
pembrolizumab. Simulations based on allometrically scaled cynomolgus monkey PK parameters 
suggested that the target EC50 concentration of 15 μg/mL should be readily attained as trough levels at 
steady- state following IV dosing of 1 mg/kg pembrolizumab every 2 weeks. A 10 mg/kg every 2 weeks 
dose represents a 40-fold dose multiple over the no observed adverse effect level (NOAEL), see 
pembrolizumab Investigator’s Brochure for more detail. The extended Phase I study tested 2 mg/kg and 
10 mg/kg administration at either every 2 or every 3 weeks. Additional PK, safety, and efficacy analysis of 
completed and ongoing multi-dose trials (1 - 10mg/kg range) has determined a flat dose of 200 mg    
Q3W corresponding to 2.5 to 3 mg/kg is to be used for all new studies. This dose used in the  expanded 
access  program  (NCT02083484) for melanoma patients who relapsed on ipilimumab was set at 2 
mg/kg. 
Publication of the multi-dose pembrolizumab monotherapy trial demonstrated the confirmed response 
rate by RECIST v1.1 in 117 patients with advanced melanoma to be 38% (95% confidence interval [CI], 
25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg/kg every 
2 weeks (52%, 95% CI, 38 to 66). The response rate did not differ significantly between patients who had 
received prior ipilimumab treatments and those who had not. Responses were durable in the majority of 
patients (median follow-up, 11 months among patients who had a response) and the overall median 
progression-free survival among 135 patients was longer than 7 months [15]. 
Of the 135 patients assessed in the 2013 publication of the Phase I trial, generalized symptoms including 
fatigue and asthenia, fever and chills, myalgias, and headaches were reported frequently but were of low 
grade. Rashes and pruritus were reported in 21% of the patients; grade 3 or 4 pruritus was reported in 
1% of the patients, and grade 3 or 4 rash in 2%. Treatment-related pneumonitis was reported in 4% of 
the patients. Grade 3 or 4 elevations of aminotransferase levels were reported in 1% of the patients. Two 
cases of grade 3 renal failure were reported. Diarrhea was reported in 20% of the patients, with a single 
case of grade 3 treatment-related diarrhea. Grade 3 hyperthyroidism  and grade 2 adrenal 
insufficiency developed in one patient. No other endocrinopathies were recorded15. Measures of efficacy 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 14
 
 
 
 
and safety resulting from this Phase I trial support administration of pembrolizumab in patients with 
advanced melanoma to achieve tumor regression without significant safety issues. 
Intratumoral plasmid interleukin-12 (pIL-12) administered by in vivo electroporation (EP) will be added 
to the treatment regimen of melanoma in this trial. Interleukin-12 (IL-12) is a 70 kilodalton protein 
consisting of two subunits linked by a disulfide bond [36]. It is a potent pleotropic cytokine, capable of 
driving cell-mediated immunity through multiple parallel mechanisms, including activation of NK cells 
and cytotoxic T lymphocytes (CTLs) as well as inhibition of regulatory T cells and myeloid-derived 
suppressor cells (MDSCs)[35-37] . Also, as a potent inducer of interferon-gamma (IFN-γ), IL-12 can drive 
upregulation of antigen processing and presentation machinery (APM) within tumors. 
IL-12 has undergone pre-clinical testing against various tumors in mice, administered as a recombinant 
protein therapy and by plasmid encoding IL-12 gene therapy. Comparative studies showed IL-12 gene 
therapy to be as efficient as IL-12 protein therapy with far less toxic side effects [16]. Delivery of IL-12 by 
gene therapy has been tested for antitumor effects and safety in the poorly immunogenic and metastatic 
B16 murine melanoma model. Intratumoral injection of pIL-12 and intratumoral injection followed by EP 
have demonstrated antitumor effect and far less toxicity than other methods of gene therapy delivery. 
Administration of intratumoral pIL-12 followed by EP results in significant growth delay when 
administered as one treatment[17] with complete tumor regression achievable in two and three 
treatment protocols18,19. EP is a physical method of delivery of compounds to tissues in vivo and was first 
reported to transfect cells in vivo with plasmid DNA in 1991 when reporter gene expression was seen in 
skin cells of mice20. In a study conducted by Lucas et al. in 2002, mice receiving intratumoral pIL-12 (50 
μg, 1μg/μL) followed by application of six 100 μs pulses with field strength of 1500 V/cm EP on day 0 
and day 7 slowed tumor growth, with 47% (8/17) showing complete regression of tumors. All mice 
experienced prolonged survival. Seven of the animals that showed complete regression and remained 
disease-free for 50 days were challenged with B16.F10 tumor cells, and 5 were resistant to tumor 
growth. Serum levels of IL-12 and IFN-γ were not significantly greater than expression in mice that 
received no treatment (P > 0.05). Infiltration of CD4+ and CD8+ T cells was seen in tumors five days after 
pIL-12 EP. 
In a follow up experiment comparing a two-treatment versus three-treatment protocol, three treatments 
(days 0, 4 and 7) under similar treatment conditions resulted in an 80% cure rate with mice free of 
tumors for >100 days, statistically significant (p<0.05) over the 60% (9 out of 15 mice) survival rate 
resulting from the two-treatment protocol. When challenged with B16.F10 cells, all 12 (100%) of the 
disease free mice in the three-treatment groups were resistant, and eight out of nine mice (88.9%) in the 
two-treatment group were resistant suggesting the development of  an immune memory response. 
These treatment protocols  were  further examined in multiple tumor and metastatic models. In 
addition, no toxicity or adverse reactions were noted in the treated mice. 
To fully characterize the potential toxicity following pIL-12 EP, C57B1/6 mice with established B16.F10 
melanoma tumors were treated on the three-treatment protocol and evaluated for weight change, tumor 
response, blood chemistry and hematology values, serum IL-12 levels and histopathologic analysis of 
multiple tissues. Two different concentrations (0.1 μg/μL and 1 μg/μL) of intratumoral injection of pIL- 
12 (50 μL) with and without EP were assessed. Focal inflammation of the kidney and focal 
glomerusclerosis at later time points were the abnormal findings seen at the higher dose. Symptoms 
associated with systemic spillage of IL-12 and corresponding increased expression of IFN-ϒ, such as 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 15
 
 
 
 
weight loss and splenomegaly were not observed. No significant serum protein IL-12 levels were seen in 
any group [21]. 
Intratumoral injection of pIL-12 followed by in vivo EP is currently under investigation in a multi- center 
Phase II trial. A Phase I trial was conducted involving seven dosing cohorts with a total of 24 patients. 
Patients received one cycle consisting of three days of treatment. Maximum total plasmid injected per 
visit ranged from 0.2-6 mg, at concentrations ranging from 0.1-1.6 mg/mL. A dose proportional increase 
in IL-12 protein expression compared to pretreatment in biopsied tumors was seen in all patients with  
no significant IL-12 spillage into circulation. Most (76%) electroporated lesions demonstrated greater 
than 20% necrosis at the time of follow-up biopsy or excision performed between 3 and 31 days after the 
last injection. Four of 19 patients who had distant disease had evidence of distant responses including 3 
complete responses in patients with progressive metastatic disease. Of these patients, 2 patients had not 
had any subsequent systemic therapy while 1 patient had received dacarbazine following pIL-12  
therapy. All three complete responses occurred in the setting of patients with disseminated progressive 
cutaneous lesions. No dose related or treatment related toxicity was seen except for transient pain and 
discomfort at the injection site [22]. 
Results from the Phase I study led to the ongoing Phase II testing of intratumoral pIL-12 (0.5 mg/mL) EP 
in 30 patients principally with in-transit cutaneous and subcutaneous metastatic melanoma or M1a 
melanoma and few patients with M1b and M1c. In this trial, one treatment cycle consists of three 
treatment days (days 1, 5 and 8) at 12-week intervals. Interim data from 21 patients in the Phase II trial, 
reported 8 of 21 patients (38%) exhibited an objective response and 11 of 18 patients with evaluable 
lesions (61%) experienced regression of non-injected lesions. Transient pain and inflammation at the 
treatment site were the most common grade 1/2 drug-related adverse events (AEs), with no grade 3/4 
drug-related AEs[23].  I 
n the main (1-year) portion of a Phase 2 study (OMS-I100) to assess safety, tolerability, and explore the 
anti-tumor activity of IT-pIL12-EP monotherapy in patients with melanoma, the overall response rate 
(ORR) by modified “skin” Response Evaluation Criteria in Solid Tumors (RECIST) in 23 evaluable patients 
was 34.8% (8/23), with 17.4% (4/23) of patients achieving a complete response (CR). The disease 
control rate (DCR = CR + partial response [PR] + stable disease [SD]) was 65.2% (15/23). Major             
(i.e., ≥30%) regression of at least 1 local lesion was seen in 64.0% (16/25) of patients. Twenty-two 
patients had at least one anatomically distinct lesion that was left untreated (i.e., non-injected, non-EP) in 
order to evaluate for an abscopal effect. Major (i.e., ≥30%) regression of at least one untreated lesion was 
observed in 31.8% (7/22) of patients. Further in the addendum cohort, overall response rate (ORR) by 
modified “skin” Response Evaluation Criteria in Solid Tumors (RECIST) in 15 evaluable patients was 
40% (6/15), with all 6 patients achieving a partial response (PR). The disease control rate (DCR = CR + 
partial response [PR] + stable disease [SD]) was 53.3% (8/15). Major (i.e., ≥30%) regression of at least 1 
local lesion was seen in 44.4% (8/20) of patients. Twenty patients had at least one anatomically distinct 
lesion that was left untreated (i.e., non-injected, non-EP) in order to evaluate for an abscopal effect. 
Major (i.e., ≥30%) regression of at least one untreated lesion was observed in 20% (5/20) of patients. 
Overall, safety data with IT-pIL12-EP are available from 118 patients with malignancies, of whom 96 
received IT-pIL12-EP as monotherapy (i.e., monotherapy patients) and 22 received IT-pIL12-EP in 
combination with pembrolizumab (i.e., combination patients). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 16
 
 
 
 
Overall, IT-pIL12-EP was well tolerated as monotherapy. The only treatment-emergent adverse events 
(TEAEs) occurring at an incidence ≥ 10% among patients treated with IT-pIL12-EP as monotherapy 
were related to the treatment administration procedure, including procedural pain (55.2%), injection 
site inflammation (14.6%), and injection site discoloration (11.5%), as well as fatigue (12.5%). For most 
patients who experienced these events, the events were assessed by the Investigator as study drug- or 
procedurally-related. No patient treated with IT-pIL12-EP monotherapy experienced a serious adverse 
reaction (SAR) (i.e., a study drug-related serious adverse event [SAE]). 
1.3 RATIONALE FOR THE PROPOSED STUDY 
Inhibition of the PD-L1/PD-1 axis with mAbs is transforming the therapeutic landscape in melanoma, 
with objective response rates (ORR) in the range of 20-50%. Unfortunately, even in melanoma, which is 
considered to be one of the most immunoresponsive types of solid tumor, the majority of patients will 
not respond to monotherapy with anti-PD-1 agents. These primary PD-1-nonresponders represent a 
significant unmet medical need that may benefit from a combination therapy tailored to the PD-1- 
nonresponder phenotype to convert them to a PD-1- responder population. 
PD-1 was shown to be expressed on activated lymphocytes including peripheral CD4+ and CD8+ T-cells, 
B cells, T regs and Natural Killer (NK) cells [24,25]. Expression has also been shown during thymic 
development on CD4-CD8- (double negative) T-cells as well as subsets of macrophages and dendritic 
cells [26]. The ligands for PD-1 (PDL-1 and PD-L2) are constitutively expressed or can be induced in a 
variety of cell types and various tumors [4, 29-31]. Patients with a brisk CD8+PD-1+ TIL population, 
usually seen in distinct clusters in association with PD-L1+ cells, often have a high probability of response 
to anti-PD-1 monotherapy. These patients benefit from a strong endogenous antitumor response,   
leading to the generation of cytotoxic T lymphocytes. On the other hand, the absence of significant 
numbers of TILs in melanoma is highly correlated with the lack of response to PD-1 therapy27. Combining 
the anti-PD-1 agent, pembrolizumab, with an agent capable of driving an effective T cell response,       
such as IL-12, may increase the immunogenicity in the nonresponder phenotype and enhance response 
to pembrolizumab. 
Intratumoral injection of pIL-12 alone has demonstrated reduced tumor volume along with peritumoral 
and intratumoral infiltrates of CD4+ and CD8+ in the poorly immunogenic and anti- PD1 refractory 
B16.F10 mouse melanoma model28. The addition of EP to mediate gene delivery supports conversion of 
the low TIL/non-immunogenic mouse model into an immunogenic one, as evidenced by tumor 
regression associated with CD4+ and CD8+ infiltrates and rejection of subsequent tumor grafts18,19. The 
dose proportional increase in IL-12 protein expression and tumor levels of IFN-ϒ seen in the Phase I trial 
further demonstrate intratumoral changes post treatment. Emerging Phase II data indicate a doubling of 
intratumoral NK cells from pre- treatment through day 11 and at day 39, and increased frequency in 
activated circulating NK cells [23]. 
This trial will assess whether response to pembrolizumab in a preselected population of patients 
determined to have low TILmelanoma can improve overall response rates when treated in combination 
with intratumoral pIL-12 EP. Patients in part A will be selected based on their TIL status and patients in 
part B will be enrolled if they are progressing on PD-1 therapy.Tissue biopsies of all patients will be 
collected prior to enrollment to assess for study eligibility. Patients in part A will be selected based on a 
flow cytometric assay, quantifying intratumoral PD-1hiCD8+CTLA4+ “exhausted” lymphocytes developed 
by investigators at UCSF[43]. The purpose of this patient pre-selection is to enrich the study population 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 17
 
 
 
 
for patients, who would be unlikely to respond to pembrolizumab as a monotherapy. Patients in part B 
will be eligible if they have received >/= 12 weeks of an anti-PD-1 therapy and have shown progression 
by RECIST by radiological confirmation or if cutaneous and subcutaneous lesions have enlarged or new 
lesions appeared. 
This multi-center, open-label, single arm trial will evaluate in total 42 patients, comparing objective 
response rates with the combination of pIL-12 EP + pembrolizumab versus pembrolizumab historical 
control rates. 
Each treatment cycle is 3 weeks. Patients will initiate treatment of pembrolizumab concurrently with the 
first cycle of intratumoral (IT) pIL-12 EP. Pembrolizumab will be administered at 200 mg once per 
treatment cycle (i.e., every 3 weeks). IT pIL-12 EP will be administered on days 1, 5 and 8 every 6 weeks 
(i.e., every odd cycle) as long as patients have accessible lesions for EP. Patients will be evaluated for 
objective response approximately every 12 weeks using RECIST v1.1 by investigator evaluation and will 
continue on therapy if they have stable disease or better at the time of disease evaluations. An 
independent central review may also be employed for response evaluations. Therapy will be given until 
disease progression or unacceptable toxicity for up to two years. The only exception will be those 
patients who experience a confirmed CR; these patients may discontinue treatment at the investigator’s 
discretion. Patients may reinitiate either therapy post-complete remission relapse if the study remains 
open and the patient meets the conditions outlined in the protocol. Patients will be followed continually 
for safety and tolerability by assessment of adverse events. 
 
1.4 CORRELATIVE STUDIES 
1.4.1 BIOMARKERS 
The primary biomarker objective is to assess the relationship between PD-L1 expression, TIL profile 
(IHC and gene expression), and anti-tumor activity of pIL-12 EP + pembrolizumab in patients. 
Investigators at UCSF have found that patients with a subset of “exhausted” TIL expressing PD- 
1hiCD8+CTLA4+, demonstrate a diminished response rate to checkpoint blockade therapy[43]. 
It is hypothesized that treatment with IT pIL-12 EP will increase TIL expression and, therefore, increase 
the likelihood of tumor regression and response to pembrolizumab. 
Response rates from the combination of IT pIL-12 EP plus pembrolizumab will be stratified by TIL status 
and PD-L1 IHC expression to insure that the study population is comparable to the historical control 
population treated with pembrolizumab as a monotherapy. The TIL/ PD-L1 status of the selected 
population will be confirmed retrospectively using at least one of the following assays: the PD-L1 IHC 
assay (clone 22C3) developed by Merck and by quantitative CD8 T cell density [42]. 
Other candidate biomarkers which will be investigated in the study may include, but are not limited to, 
the following: 
<0000> 
RNA and DNA profiling in biopsy tissue 
<0000> 
Multispectral fluorescent immunohistochemistry from immune subsets in biopsy tissue 
<0000> 
Quantitative RNA expression of candidate genes of interest 
<0000> 
Cytokine/chemokine profiles in peripheral blood 
<0000> 
Antigen specific cellular and humoral immune profiles in peripheral blood 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 18
 
 
 
 
Statistical details for the biomarker analyses are described in Section 8 (Statistical Considerations and 
Evaluation of Results). Tissue and blood samples will be collected at the time points described in Section 
6 (Study Procedures and Observations). 
 
1.4.2 FUTURE BIOMEDICAL RESEARCH 
Future biomedical research on blood and leftover tumor biopsy specimens will be performed on 
collected samples during this clinical trial. This research may include genetic analyses (DNA), gene 
expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or the measurement of 
other analytes. This research is for biomarker testing to address emergent questions not described 
elsewhere in the protocol (as part of the main biomarker correlative objectives). The objective is to 
explore and identify biomarkers that inform scientific understanding of this therapeutic treatment and 
tumor biology responses to IT pIL-12 EP. Such retrospective studies will be conducted with appropriate 
statistical considerations and evaluation of results as described in Section 8. Tissue and blood samples 
will be collected at the time points described in Section 6 (Study Procedures and Observations). 
 
 
2 OBJECTIVES OF THE STUDY 
2.1 PRIMARY 
• 
To assess the anti-tumor efficacy of the combination of intratumoral pIL-12 EP and 
pembrolizumab in patients with low TIL melanoma using RECIST v1.1. 
 
 
2.2 SECONDARY 
a) To assess safety and tolerability of the combination of IT pIL-12 EP and pembrolizumab. 
b) To assess  duration of response in  melanoma patients  treated with  the combination of IT 
pIL-12 EP and pembrolizumab 
c) To assess twenty-four week landmark progression free survival (PFS at 24) in 
melanoma patients treated with the combination of IT pIL-12 EP and pembrolizumab. 
d) To assess median progression free survival (PFS) in melanoma patients treated with the 
combination of IT pIL-12 EP and pembrolizumab. 
e) To assess  overall survival (OS) in melanoma patients  treated with  the combination of IT pIL- 
12 EP and pembrolizumab. 
f) To assess  Best overall objective response rate determined by immune related- Response 
Criteria (irRC) 
g) To assess patients stratified based on TIL status for the endpoints described in bullets 2a through 
2f 
 
 
2.3 EXPLORATORY OBJECTIVES, OTHER ASSESSMENTS 
1) To investigate the relationship between candidate efficacy biomarkers and anti-tumor activity of IT 
pIL-12 EP + pembrolizumab: 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 10
IT-pIL12-EP and anti-PD-1
Page 19
 
 
 
 
a) To evaluate changes in PD-L1 expression and TIL profile post-treatment and its correlation with 
response to IT pIL-12 EP + pembrolizumab. 
b) To investigate other biomarkers  (e.g., PD-L1, interferon pathway activation, antigen 
presentation and processing machinery (APM) upregulation) that may correlate with tumor 
responses. 
c) To investigate immune responses in peripheral blood (e.g., CD4/CD8 T cells, NK cells, circulating 
FoxP3+ cells). 
d) To define presence and activity of immune cell subpopulations including but not limited to 
IDO+pDC, suppressor macrophages, and NK cells within tumor biopsies. 
 
2) To explore biomarkers that inform scientific understanding of this therapeutic treatment through 
analysis of specimens retained for Future Biomedical Research. 
 
2.4 ENDPOINTS 
2.4.1 PRIMARY ENDPOINTS 
Best overall objective response rate (ORR), CR + PR, within 24 weeks of first treatment with pIL-12 EP 
and pembrolizumab will be determined using RECIST v1.1 by investigator evaluation and compared 
against historical rates for pembrolizumab as a monotherapy in a similar population. An independent 
central review may also be employed for response evaluations. The response rate of patients  in part A 
with low TIL status on the screening flow cytometric assay is estimated at 12.5% based on the assay's 
false negative rate in this population and the rate of pseudoprogression by RECIST of patients is part B is 
the same. . 
2.4.2 SECONDARY ENDPOINTS 
Safety and tolerability is defined by assessment of adverse events. These will be assessed using the NCI 
CTCAE version 4.0. 
Duration of response (DOR) for those experiencing CR or PR is the number of days from the initial 
documentation of an objective response to the most current evaluation of that response (censored 
duration) or to documentation of progression. 
 
 
Twenty-four week landmark progression free survival (PFS at 24) is defined as the percentage of 
patients, who have progressed at the 24 week time point. 
Progression free survival (PFS) is defined as the duration between the date of treatment initiation to the 
first date of either disease progression or death. 
Overall survival (OS) is defined as the duration between the date of treatment initiation to the date of 
death, regardless of the cause of death. 
Best overall objective response rate, CR + PR, is determined by immune related-Response Criteria (irRC). 
2.4.3 EXPLORATORY ENDPOINTS 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 20
 
 
Co-primary candidate biomarkers to be investigated in this study include PD-L1 expression levels 
assessed by IHC, and TIL profile assessed by CD8 T cell density in tumor tissue. 
Changes in PD-L1 expression will be assessed pre- and post-treatment using one or both of the following 
immunohistochemical evaluations: 
(1) the Merck developed PD-L1 IHC assay (clone22C3) with a stringent cut-off of <1% in tumor or 
stromal cells of the tumor environment. 
(2) an assay developed by Tumeh/UCLA[42] is now being managed at the Rosenblum lab at UCSF with a 
low TIL cut-off of <600 CD8 cells/mm2. If tumor samples demonstrate that the combination therapy 
converts tumors from low TIL to high TIL but without a corresponding increase in ORR, then the 
hypothesis that enhancing TILs will increase pembrolizumab efficacy can be rejected. Changes in other 
biomarkers and immune responses in tissue and blood will be assessed for association with clinical 
outcome (efficacy endpoints). 
 
 
3 STUDY DESIGN 
3.1 CHARACTERISTICS 
This is a multi-center, Phase II, open label, single-arm trial of intratumoral pIL-12 EP in combination with 
pembrolizumab in patients with melanoma. The best overall objective response rate of the combination 
will be compared to negative PD-L1 historical rates for pembrolizumab as a monotherapy. Patients will 
be evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that quantifies 
intratumoral PD-1hiCD8+CTLA4+ “exhausted” lymphocytes in the tumor. Part B will enroll patients who 
have or are failing pembrolizumab at least 12 weeks after starting PD-1 Antibody alone or in 
combination. The study will assess post-treatment increase of immunogenicity in melanomas and the 
enhancement of pembrolizumab responses in this population. 
 
3.2 NUMBER OF SUBJECTS 
This trial is planned for 42 evaluable patients. Patients will be evaluated in 2 parts. Part A (22 patients) 
will be selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ 
“exhausted” lymphocytes in the tumor. Part B will enroll 20 patients who have or are failing 
pembrolizumab at least 12 weeks after starting PD-1 antibody alone or in combination, or, who have 
been selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ 
“exhausted” lymphocytes in the tumor. 
 
3.3 ELIGIBILITY CRITERIA 
Patients must have baseline evaluations performed prior to the first dose of study drug and must meet 
all inclusion and exclusion criteria.  Patients are intended to have an untreated lesion when there are 3 
or more visible, treatable lesions present. In addition, the patient must be thoroughly informed about all 
aspects of the study, including the study visit schedule and required evaluations and all regulatory 
requirements for informed consent. The written informed consent must be obtained from the patient 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 21
 
 
prior to enrollment. The following criteria apply to all patients enrolled onto the study unless otherwise 
specified. 
 
 
3.3.1 INCLUSION CRITERIA 
1. Patients must have histological or cytological diagnosis of melanoma with progressive locally 
advanced or metastatic disease that is not amenable to definitive local therapy with curative intent. 
2. At least one measurable tumor accessible for intratumoral injection and EP on investigator’s 
assessment. 
3. Patients may have had prior chemotherapy or immunotherapy or radiation therapy. All prior 
therapies must be stopped 4 weeks prior to first dose of study treatment, with the exception of patients 
who have received ipilimumab, which must be stopped 6 weeks prior to first dose of study treatment. 
Patients are prohibited from receiving live vaccines within 30 days prior to first dose of study treatment. 
4. Age ≥ 18 years 
5. Part A: Patient has agreed to two newly obtained tumor biopsies and as required re-biopsies (that can 
be biopsied on investigator’s assessment) and to providing the acquired tissue for biomarker analysis. 
Analysis of one of the fresh biopsy samples for PD-1hiCD8+CTLA4hi in the CD8+CD45+   gate based on flow 
cytometry will be done. A second fresh biopsy sample is required for further biomarker analysis and 
confirmation at a later date of low PD-L1 expression using an IHC assay for PD-L1 expression. A valid 
flow cytometry result is not required for study participation, but repeated biopsy for reanalysis is 
strongly recommended for patient with insufficient TILs in the first tissue sample. 
Or 
Part B: Anti-PD-1 non-responders are defined as those showing disease progression according to RECIST 
v1.1 after at least 12 weeks of therapy with a PD-1 antibody either alone or in combination with 
approved checkpoint inhibitor or targeted therapies according to their label. There is no serological 
requirement, 
 
6. Life expectancy of at least 6 months. 
7. ECOG performance status 0-1. 
8. Adequate organ function within 4 weeks of administration of study therapy. 
 
Lactate dehydrogenase (LDH) 
<4 x upper limit of normal (ULN) 
Adequate hematological function: 
Absolute neutrophil count (ANC) 
≥1,500/μL 
Platelets 
≥100,000/μL 
Hemoglobin 
≥9 g/dL 
Adequate hepatic function: 
Serum total bilirubin 
≤1.5 x ULN OR Direct bilirubin ≤ ULN for 
patients with total bilirubin levels >1.5 ULN 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 22
 
 
AST (SGOT) and ALT (SGPT) 
≤2.5 x ULN OR ≤5 x ULN for patients with liver 
metastases 
Adequate renal function: 
Serum creatinine 
≤1.5 x ULN 
Coagulation: 
International normalized  ration (INR) 
or Prothrombin Time (PT) 
≤1.5 x ULN (Only if not using anticoagulants1) 
Activated  partial thromboplastin time 
(aPTT) 
≤1.5 x ULN (Only if not using anticoagulants1) 
1If patient is receiving anticoagulants, then value must be within therapeutic range for the 
condition that patient is being treated for. 
 
9. Female patient of childbearing potential has a negative serum or urine pregnancy test within 14 days 
prior to administration of study therapy. 
10. The effects of pIL-12 EP and pembrolizumab on the developing human fetus  are unknown. For 
this reason women of child-bearing potential (not free from menses for >2 years, post 
hysterectomy/oophorectomy, or surgically sterilized) must agree to use two methods of contraception,  
or abstain from heterosexual activity, during participation in study, from the time of consent through 120 
days after the last dose of study therapy. The two methods must include at least one “barrier method”. 
Barrier methods are diaphragms, cervical caps, cervical shields, male condoms, and female condoms. The 
second method of contraception may be another barrier method, a copper containing IUD, spermicidal 
foams, sponges and films, or hormone-based contraception (for example, hormone pills, hormone rings, 
hormone patches, hormone-releasing IUDs, or Depo Provera). Men with partners who are capable of 
getting pregnant must agree to use one of the barrier methods of contraception listed above during 
participation in the study, starting with the first dose of study drug through 120 days after the last dose of 
study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is 
participating in this study, she should inform her treating physician immediately. 
11. Ability to understand a written informed consent document, and the willingness to sign and date it. 
 
 
3.3.2 EXCLUSION CRITERIA 
1. Patient is currently participating or has participated in a study of an investigational agent or using an 
investigational device within 4 weeks of administration of study therapy. 
2. Patient is expected to require any other form of antineoplastic therapy while on study; including 
systemic chemotherapy, biological therapy, immunotherapy not specified in this protocol. 
3. Patient has uveal melanoma. 
4. Patient  has   known  active  central  nervous  system  (CNS)  metastases   and/or carcinomatous 
meningitis. Patients with previously treated brain metastases may participate provided they are 
clinically stable without the use of systemic steroids for at least 8 weeks prior to study entry. 
5. Patient has risk factors for bowel obstruction or bowel perforation (examples include but not limited 
to a history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 23
 
 
6. Patient previously had a severe hypersensitivity reaction to treatment with another mAb. 
7. Patient has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis or 
interstitial lung disease. 
8. Patient has active infection at time of study entry that require systemic antibiotics and/or 
with an oral temperature of ≥ 38.3°C (100.9°F) within 5 days of first treatment. 
9. Patients with electronic pacemakers or defibrillators are excluded from this study, as the effect of 
electroporation on these devices is unknown. Patients with lower extremity lesions may be discussed 
with the medical monitor. 
10. Patient has an active autoimmune disease or a documented history of autoimmune disease or 
syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or 
resolved childhood asthma/atopy would be exception to this rule. Patients that require intermittent use 
of bronchodilators or local steroid injections would not be excluded from the study. Patients with 
hypothyroidism that is stable on hormone replacement will not be excluded from the study. 
11. Patient has  a medical condition that requires chronic  systemic  steroid therapy or requires any 
other form of immunosuppressive medication. However, patients using physiologic replacement doses of 
hydrocortisone, or its equivalent, will be considered eligible for this study; up to 20 mg hydrocortisone 
(or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg of prednisone) in the 
evening. 
12. Pregnant women are excluded from this study because the potential for teratogenic or abortifacient 
effects upon treatment with  pIL-12 EP + pembrolizumab is  unknown. Because there is an unknown 
but potential risk for adverse events in nursing infants secondary to treatment of the mother with pIL-12 
EP + pembrolizumab breastfeeding should be discontinued if the mother is treated with pIL-12 EP + 
pembrolizumab. 
13. Patients with symptomatic ascites or pleural effusion. A patient who is clinically stable following 
treatment for these conditions is eligible. 
14. Patient is HCV Ab positive or HBSAg positive 
 
 
3.4 DURATION OF THERAPY 
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the discretion 
of the Investigator should any untoward effect occur. In addition, a subject may be withdrawn by the 
Investigator or the Sponsor-Principal Investigator if enrollment into the trial is inappropriate, the trial 
plan is violated, or for administrative and/or other safety reasons. 
In the absence of treatment delays due to adverse events, treatment may continue as long as the patient 
continues to benefit from the treatment or until: 
• 
The subject or legal representative withdraws consent 
• 
Confirmed radiographic disease progression 
o 
Note: For unconfirmed radiographic  disease  progression, patients  should 
continue treatment at the discretion of the Investigator 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 24
 
 
o 
Note: A subject may be granted an exception to continue on treatment with 
confirmed radiographic progression if clinically stable or clinically improved. 
• 
Inter-current illness that prevents further administration of treatment 
• 
The subject has a confirmed positive serum or urine pregnancy test 
• 
Unacceptable adverse event(s) 
• 
Subject decides to withdraw from the study 
• 
Significant patient non-compliance with protocol 
• 
Subject was lost to follow-up 
• 
General or specific changes in the patients’ condition render the patient unacceptable for 
further treatment in the judgment of the Investigator. 
• 
Patients who have a confirmed complete response by two scans ≥4 weeks apart and who 
have been on treatment for at least 6 months may discontinue pembrolizumab treatment at the 
discretion of the Investigator after receiving at least two doses beyond the initial determination 
of CR. Patients may enter retreatment for post-complete remission relapse ONLY if they meet 
defined criteria (see Section 5.1.2). 
• 
Completed 24 months of study treatment 
Note: 24 months of study medication is calculated as the interval from the date of first dose 
regardless of missed or skipped treatment. After 24 months, subjects may continue study treatment 
if approved by the Principal Investigator, OncoSec Medical, and Merck. Subjects who stop study 
treatment after 24 months may be eligible for up to one year of additional study treatment if they 
progress after stopping study treatment provided they meet the requirements detailed in Section 
5.1.2. 
• 
Administrative reasons 
 
 
3.5 DURATION OF FOLLOW UP 
The Safety Follow-up visit procedures are listed in Section 6 (Study Procedures and Observations). After 
the end of treatment, each subject will be followed for 30 days for adverse event monitoring (serious 
adverse events will be collected for 90 days after the end of treatment as described in Section 7.6). For 
subjects who discontinue for reasons other than progressive disease, every attempt should be made to 
continue monitoring their disease status by radiologic imaging. Monitoring should continue (1) until start 
of a new anti-cancer treatment, (2) until documented disease progression, or (3) until death,      
whichever occurs first. Radiographic imaging in follow-up may be performed as clinically indicated or 
per local standard of care. Each subject will be followed for overall survival collecting data on subsequent 
treatments and responses where possible, until death, withdrawal of consent, or the end of the study, 
whichever occurs first. 
 
 
3.6 RANDOMIZATION PROCEDURES 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 25
 
 
This is not a randomized trial. 
 
 
3.7 STUDY TIMELINE 
3.7.1 PRIMARY COMPLETION 
The study will reach primary completion approximately 18 months from the time the study opens to 
accrual. However, primary completion will depend on the rate of patient enrollment. 
 
 
3.7.2 STUDY COMPLETION 
The study is anticipated to complete in ~24 months from the time the study opens to accrual. However, 
the study duration will depend on the rate of patient enrollment. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 26
 
4 STUDY DRUGS 
4.1 DESCRIPTION, SUPPLY AND STORAGE OF INVESTIGATIONAL DRUGS 
The Investigator shall take responsibility for and shall take all steps to maintain appropriate records and 
ensure appropriate supply, storage, handling, distribution and usage of investigational product in 
accordance with the protocol and any applicable laws and regulations. 
 
 
4.1.1 PLASMID INTERLEUKIN-12 (PIL-12) 
Classification 
DNA plasmid vector (pUMVC3-hIL-12-NGVL331, referred to as “pIL-12”), expressing IL-12 gene, 
contains the human IL-12 p35 and p40 subunits that are separated by an internal ribosomal entry site 
and are driven by a single CMV promoter. 
 
 
 
 
Figure 1: The structure of DNA plasmid vector expressing Interleukin-12 
Mechanism of Action 
pIL-12 cDNA plasmid is a nonviral, high copy number plasmid designed to achieve a transient 
transfection of the host cell and high level of IL-12 protein expression. EP following intratumoral pIL-12 
injection delivers controlled electrical pulses in a square wave pulse pattern, yielding optimal 
transmembrane potential for electroporation to occur39. The electroporation pulses are between six 
hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle 
electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse 
delivery is rotated clockwise to the next opposing needle pairs until a total of six pulses are delivered to 
complete the electroporation sequence. Six pulses at a field strength (E+) of 1500 V/cm and pulse width 
of 100 μs at 1-second intervals will be administered to each previously injected tumor. 
IL-12 is a 70 kilodalton protein consisting of two subunits, 40 kD and 35 kD, linked by a disulfide bond36. 
It is a potent pleotropic cytokine capable of promoting the development of a T helper 1 response, 
inducing the  production of IFN-gamma and increasing the  proliferation and cytotoxicity of NK and T 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 27
 
 
cells37. Studies have shown that IL-12 also acts to up-regulate the expression of HLA class I and II, and 
ICAM 1, on human melanoma cells, which may increase their immunogenicity. In addition, IFN increases 
MHC I expression on B16.F10 melanoma cells32. IL-12 immunotherapy also results in the inhibition of 
angiogenesis through mechanisms not thoroughly elucidated38. 
 
 
Contraindications 
Patients may receive other medications that the Investigator deems to be medically necessary, with the 
specific exception of prohibited concomitant medications described in Section 6.2.3. 
Availability 
Plasmid interleukin-12 (pIL-12) is formulated in phosphate buffered saline (PBS) for direct intratumoral 
injection following by in vivo EP. GMP-grade pIL-12 is manufactured by VGXI USA and available batches 
will be supplied as 2.0 mL vials at a concentration of 0.5 mg/mL and fill volume of 1.5 mL. 
Storage and handling 
- 
Clinical supplies  must be stored in a secure,  limited-access  location under the storage 
conditions specified on the label. 
Receipt and dispensing of trial medication must be recorded by an authorized person at the trial site. 
- 
Clinical supplies may not be used for any purpose other than that stated in the protocol.  For 
further, specific details of plasmid IL-12 storage, handling and preparation, please refer to the 
study-specific pharmacy manual. Only authorized Investigators listed on the form FDA 1572 will 
administer the plasmid injection and EP. 
Side Effects 
- 
Complete and updated adverse event information is  available in the  Investigational Drug 
Brochure/Investigator’s Brochure. 
4.1.2 PEMBROLIZUMAB 
Classification 
- 
Pembrolizumab is a potent and highly selective humanized mAb of the IfG4/kappa isotype 
designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. 
Mechanism of Action 
- 
Complete information is available in the Investigational Drug Brochure. 
Metabolism 
- 
Complete information is available in the Investigational Drug Brochure. 
Contraindications 
- 
Patients may receive other medications that the Investigator deems to be medically necessary, 
with the specific exception of prohibited concomitant medications described in Section 6.2.3. 
Availability 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 28
 
 
- 
Clinical Supplies will be provided by Merck as summarized in Table 1. 
Table 1 Product Descriptions 
 
Product Name & Potency 
Dosage Form 
Pembrolizumab 100 mg/ 4mL 
Solution for Injection 
 
Storage and handling 
- 
Clinical supplies  must be stored in a secure,  limited-access  location under the storage 
conditions specified on the label. 
Receipt and dispensing of trial medication must be recorded by an authorized person at the trial site. 
Clinical supplies may not be used for any purpose other than that stated in the protocol. 
Side Effects 
- 
Complete and updated adverse event information is  available in the  Investigational Drug 
Brochure. 
 
 
4.2 
DRUG ACCOUNTABILITY 
The investigational pharmacist or authorized designee will manage drug accountability records. 
 
 
4.3 
DRUG ORDERING 
UCSF will obtain pembrolizumab directly from pharmaceutical company Merck, as study supply. The 
pharmaceutical company or a 3rd party vendor will supply pembrolizumab to the investigational sites 
(section 4.6). BioStorage Technologies, Indianapolis, IN, a biostorage vendor utilized by OncoSec Medical, 
will be supplying the pIL-12 to the investigational sites. 
 
4.4 
PACKAGING AND LABELING OF STUDY DRUGS 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. 
 
 
4.5 
CLINICAL SUPPLIES DISCLOSURE 
This trial is open-label; therefore, the subject, the trial site personnel, the Sponsor-Principal Investigator 
and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text; 
random code/disclosure envelopes or lists are not provided. 
 
 
4.6 
RETURNS AND RECONCILIATION 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 29
 
 
The Investigator is responsible for keeping accurate records of the clinical supplies received from Merck, 
OncoSec or designee, including the amount of all supplies remaining at the conclusion of the trial. 
Upon completion or termination of the study, all unused and/or partially used investigational product 
will be destroyed at the site per institutional policy. It is the Investigator’s responsibility to arrange for 
disposal of all empty containers, provided that procedures for proper disposal have been established 
according to applicable federal, state, local and institutional guidelines and procedures, and provided 
that appropriate records of disposal are kept. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 30
 
5 
TREATMENT PLAN 
5.1 
DOSAGE AND ADMINISTRATION 
Treatment will be administered on an outpatient basis 
 
Study Drug 
Dose 
Route 
Schedule 
Cycle Length 
 
 
Pembrolizumab 
 
 
200 mg 
 
 
Intravenous 
 
Day  1  for EVERY cycle 
 
 
 
3 weeks 
(21 
days) 
 
pIL-12 
¼ tumor volume at 
concentration of 0.5 mg/mL1 
Intratumoral2 
Days  1, 5,  8  of each 
odd cycle 
 
Note: pIL-12 should be given first followed by a 60 minute observation period between the two treatments. 
 
1 
Accessible tumors for treatment will be measured in centimeters and ¼ tumor volume will be calculated 
for each tumor selected for treatment: ¼ tumor volume = [(longest diameter in cm)(perpendicular 
diameter in cm)2]/8; a minimum of 0.1 mL per lesion for lesions <0.1 cm3  in ¼ volume will be 
administered. The maximum plasmid injection volume per patient per day will not exceed 20 mL. 
2 
Immediately following intratumoral injection, six pulses at field strengths (E+) of 1500 V/cm and pulse 
width of 100 μs at 1-second intervals will be administered to each previously injected tumor (see Section 
5.1.1.1). 
 
Thus the timing resembles 
 
[start]  Cycle 1 Pembrolizumab and pIL-12 
[3weeks] Cycle 2 Pembrolizumab 
[6weeks] Cycle 3 Pembrolizumab and pIL-12 
[9weeks] Cycle 4 Pembrolizumab 
[12weeks ] Cycle 5 Pembrolizumab and pIL-12 and so forth. 
 
 
5.1.1 TIMING OF DOSE ADMINISTRATION 
All trial treatments are planned to be administered on an outpatient basis. Intratumoral pIL-12 should 
be given first followed by a minimum of 60 minutes observation period between the two treatments. 
 
 
Pembrolizumab administration 
Pembrolizumab should be administered on Day 1 of each cycle (±3days) after all procedures / 
assessments have been completed as detailed in the Study Procedures and Observations (Section 6.0), 
and after intratumoral IL-12-EP administration. Pembrolizumab will be administered as a 30 minute IV 
infusion (treatment cycle intervals may be increased due to toxicity as described in Section 5.2). Sites 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 31
 
 
should make every effort to target infusion timing to be as close to 30 minutes as possible. However, 
given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is 
permitted (i.e., infusion time is 30 minutes: -5 min/+10 min). 
The separate Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, preparation of the infusion fluid, and administration. 
 
 
Intratumoral pIL-12 Electroporation 
Intratumoral pIL-12 followed by EP may be administered at each odd cycle as long as the subject has at 
least one accessible superficial lesion (ASL) for treatment. An ASL is defined as meeting the following 
criteria; (1) at least 0.3 cm x 0.3 cm in longest perpendicular diameters, (2) in a suitable location for 
application of electroporation. In a case where a subject may have multiple ASLs, the maximum number 
of lesions should be treated at each cycle, keeping in mind, (1) patient tolerability, and (2) not to exceed 
the maximum daily dose of 20 mL. Prior to initiation of a new treatment cycle of  pIL-12 EP, the 
Investigator will determine ASLs for treatment during that cycle. The same ASLs should be treated on 
each day of the cycle (i.e. Days 1, 5, 8). Previously treated, previously identified lesions present at  
baseline that were left untreated, and new lesions which appear during the course of the study that meet 
the definition of an ASL may be treated as long as the maximum plasmid injection volume per patient per 
day does not exceed 20 mL. If no ASLs are present at subsequent cycles, the subject may skip that cycle of 
pIL-12 and continue on the study calendar. When feasible one lesion should remain untreated during 
Cycle 1 to permit biopsy of an untreated lesion, see Section 6.1.2.3. 
 
5.1.2 POST-COMPLETE REMISSION RELAPSE ADMINISTRATION 
Duration of therapy may continue until patients have a confirmed complete response by two scans ≥4 
weeks apart and who have been on treatment for at least 6 months. Discontinuation of the study regimen 
(IT-pIL12-EP and pembrolizumab) may occur at the discretion of the Investigator after receiving at least 
two doses of pembrolizumab beyond the initial determination of CR. 
 
 
Patients may reinitiate the full study regimen upon relapse if the study remains open and the patient 
meets the following conditions: 
1. Stopped treatment after attaining an investigator-determined confirmed CR by RECISTv1.1 
2. Was treated for at least 24 weeks with pembrolizumab before discontinuing therapy 
3. Received at least two treatments with pembrolizumab beyond the date when the initial CR 
was declared 
4. Experienced an investigator-determined progression after stopping treatment 
5. Did not receive any anti-cancer treatment since the last dose of treatment 
6. Have a performance status of 0 or 1 on the ECOG Performance Scale 
7. Demonstrate adequate organ function as follows: 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 32
 
 
Adequate hematological function: 
 
Absolute neutrophil count (ANC) 
≥1,500/μL 
Platelets 
≥100,000/μL 
Hemoglobin 
≥9 g/dL 
Adequate hepatic function: 
 
Serum total bilirubin 
≤1.5 x upper limit of normal (ULN) OR Direct 
bilirubin ≤ ULN for patients with total bilirubin levels 
>1.5 ULN 
AST (SGOT) and ALT (SGPT) 
≤2.5 x ULN OR ≤5 x ULN for patients with liver 
metastases 
Adequate renal function: 
 
Serum creatinine 
≤1.5 x ULN 
Coagulation: 
 
International normalized ration (INR) 
or Prothrombin Time (PT) 
≤1.5 x ULN (Only if not using anticoagulants1) 
Activated partial thromboplastin time 
(aPTT) 
≤1.5 x ULN (Only if not using anticoagulants1) 
1If patient is receiving anticoagulants, then value must be within therapeutic range for that 
condition that patient is being treated for. 
 
8. Female patient of  childbearing potential should have a negative serum  or urine 
pregnancy test within 14 days prior to receiving retreatment 
9. Women of child-bearing potential (not free from menses for >2 years, post 
hysterectomy/oophorectomy, or surgically sterilized) must agree to use two methods of 
contraception, or abstain from heterosexual activity, during participation in study, starting with 
the first study treatment from the time of consent through 120 days after the last dose of study 
therapy. The two methods must include at least one “barrier method”. Barrier methods are 
diaphragms, cervical caps, cervical shields, male condoms, and female condoms. The second 
method of contraception may be another barrier method, a copper containing IUD, spermicidal 
foams, sponges and films, or hormone-based contraception (for example, hormone pills, hormone 
rings, hormone patches, hormone- releasing IUDs, or Depo Provera). Men with partners who 
are capable of  getting pregnant must agree to use one of the barrier methods of contraception 
listed above during participation in the study, starting with the first dose of study drug through 
120 days after the last dose of study therapy. 
Patients who restart treatment will be retreated at the same 21 day cycle length they received 
upon initial treatment. The assessments will follow the main study calendar and will be noted in 
the CRFs as “re-treatment” cycles. 
 
5.1.3 OTHER MODALITY(IES) OR PROCEDURES 
5.1.3.1 Electroporation (EP) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 33
 
 
Prior to plasmid injection, using sterile precautions, 1% lidocaine may be injected around the lesion 
intended for IT-pIL-12 EP to obtain local anesthesia. In addition, the patient may be given analgesics or 
anxiolytics as necessary prior to or during treatment. After injecting the plasmid solution into the 
accessible tumor, a sterile applicator containing 6 stainless steel electrodes arranged in a circle will be 
placed into or around the tumor. The applicator will be connected to the power supply and six pulses at a 
field strength (E+) of 1500 V/cm and pulse width of 100 μs at 1-second intervals will be administered to 
each previously injected tumor. EP following intratumoral pIL-12 injection delivers controlled electrical 
pulses in a square wave pulse pattern, yielding optimal transmembrane potential for electroporation to 
occur [39]. The electroporation pulses are between six hexagonal opposing needle electrodes. After the 
first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is 
pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing 
needle pairs until a total of six pulses are delivered to complete the electroporation sequence. When 
multiple tumors are being injected on the same day, EP should be performed immediately after the 
plasmid injection for each tumor. Once a tumor has been completely treated, the next tumor can be 
injected with plasmid and immediately electroporated. 
The OncoSec Medical System EP device used to deliver the plasmid consists of two main components: (1) 
a sterile disposable electrode applicator (OMS Applicator) with needle electrodes (OMS Applicator Tip) 
and (2) an electric pulse device, the OMS Electroporation Therapy Generator (OMS Generator). The OMS 
Applicator connects to the OMS Generator via a cable with a proximal connector.  An OMS 
Electroporation Therapy Printer (OMS Printer) may be optionally used to generate a real time event log 
of the electroporation treatment information used during the treatment. Additional details regarding 
handling of the device are provided in the OncoSec Medical System Operator’s Manual. 
 
 
5.2 
DOSE MODIFICATIONS AND DOSING DELAYS 
Treatment or visit delays for public holidays or weather conditions do not constitute a protocol violation. 
The following dose modification rules will be used with respect to potential toxicity. Toxicity will be 
assessed according to the NCI Common Terminology Criteria for Adverse Events Version4.0 (CTCAE  
v4.0). 
 
 
5.2.1.1 Dose Modification 
Pembrolizumab will be withheld for drug-related Grade 4 hematologic toxicities, non- hematological 
toxicity ≥ Grade 3 including laboratory abnormalities, and severe or life- threatening AEs as per Table 2 
below. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 34
 
 
 
Table 2 Dose modification guidelines for drug-related adverse event 
 
Toxicity 
Grade 
Hold 
Pembro 
lizumab 
(Y/N) 
Hold 
pIL-12 
EP 
(Y/N) 
Timing 
for 
restarting 
treatment 
Dose/Schedule 
for restarting 
treatment 
Discontinue 
Subject (after 
consultation 
with Sponsor) 
1, 2, 3 
No 
No 
N/A 
N/A 
N/A 
Hematological 
Toxicity 
4 
Yes 
Yes 
Toxicity 
resolves 
to Grade 
0-1 for 
baseline 
Restart study 
treatment Day 1 at 
the next scheduled 
treatment cycle. 
The next treatment 
cycle may begin 
sooner than 
scheduled per 
Investigator 
discretion following 
discussion        
with the OncoSec 
Medical      
Monitor. 
Toxicity does 
not resolve 
within 12 weeks 
of last infusion 
 
Permanent 
discontinuation 
should be 
considered for 
any severe or 
life-threatening 
event 
1 
No 
No 
N/A 
N/A 
N/A 
2 
Conside 
r 
withholdi 
ng for 
persiste 
nt 
sympto 
ms 
No 
Toxicity 
resolves 
to Grade 
0-1 for 
baseline 
Clinical AE 
resolves within 4 
weeks: Same 
dose and schedule 
 
Clinical AE does 
not resolve within 
4 weeks: May 
increase the 
dosing interval by 
1 week for each 
occurrence 
Toxicity does 
not resolve 
within 12 weeks 
of last infusion 
Non- 
hematological 
toxicity 
 
Note: Exception 
to be treated to 
grade 1 toxicity 
<0000> 
Grade 2 
alopecia 
<0000> 
Grade 2 
fatigue 
3, 4 
Yes 
No 
Toxicity 
resolves 
to Grade 
0-1 or 
baseline 
Restart study 
treatment Day 1 at 
the next scheduled 
treatment cycle. 
The next treatment 
cycle may begin 
sooner than 
scheduled per 
Investigator 
discretion following 
discussion        
with the OncoSec 
Medical      
Monitor. 
Toxicity does 
not resolve 
within 12 weeks 
of last infusion 
 
Permanent 
discontinuation 
should be 
considered for 
any severe or 
life-threatening 
event 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 35
 
 
 
In case toxicity does not resolve to Grade 0-1 or baseline within 12 weeks after 
last infusion, trial treatment should be discontinued after consultation with the 
Sponsor-Principal Investigator. With Investigator and Sponsor-Principal 
Investigator agreement, subjects with a laboratory adverse event still at Grade 
2 after 12 weeks may continue treatment in the trial only if asymptomatic and 
controlled. 
Subjects who experience a recurrence of the same severe or life-threatening event at the same grade or 
greater with  re-challenge of  pembrolizumab should be discontinued from  trial treatment. 
 
 
5.3 MONITORING AND TOXICITY MANAGEMENT 
Each patient receiving IT pIL-12 EP + pembrolizumab will be evaluable for safety. Safety will be assessed 
during the study by documentation of adverse events (AEs), clinical laboratory tests, physical 
examination, vital sign measurements, and Eastern Cooperative Oncology Group (ECOG) performance 
status. 
Each patient will be assessed periodically for the development of any toxicity as outlined in Section 6 
Study Procedures and Observations. Toxicity will be assessed according to the NCI CTCAE v4.0.   Dose 
adjustments will be made according to the system showing the greatest degree of toxicity. 
 
 
5.4 RESCUE MEDICATIONS & SUPPORTIVE CARE 
5.4.1 SUPPORTIVE CARE GUIDELINES 
Subjects should receive appropriate supportive care measures as deemed necessary by the treating 
Investigator. Suggested supportive care measures for the management of adverse events with potential 
immunologic etiology are outlined below. Where appropriate, these guidelines include the use of oral or 
intravenous treatment with corticosteroids as well as additional anti-inflammatory agents if symptoms 
do not improve with administration of corticosteroids.  Note that several courses of steroid tapering 
may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, 
attempts should be made to rule out other causes such as metastatic disease or bacterial or viral 
infection, which might require additional supportive care. The treatment guidelines are intended to be 
applied when the investigator determines the events to be related to pembrolizumab. 
 
Note: if after the evaluation the event is determined not to be related, the investigator does not need to 
follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for dose modification. 
 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
 
<0000> 
Pneumonitis: 
o 
For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 36
 
 
o For Grade 3-4 events, immediately treat with intravenous steroids. Administer additional 
anti-inflammatory measures, as needed. 
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid 
administration. 
<0000> 
Diarrhea/Colitis: 
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as 
peritoneal signs and ileus). 
 
o 
All subjects who experience diarrhea/colitis should be advised to drink liberal quantities 
of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should be 
substituted via IV infusion. For Grade 2 or higher diarrhea, consider GI consultation and 
endoscopy to confirm or rule out colitis. 
o 
For Grade 2 diarrhea/colitis, administer oral corticosteroids. 
o 
For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by high dose 
oral steroids. 
o 
When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks. 
<0000> 
Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 
Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis (DKA) 
o 
For T1DM or Grade 3-4 Hyperglycemia 
 
Insulin replacement therapy is recommended for Type I diabetes mellitus and for 
Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
 
Evaluate  patients  with  serum  glucose  and  a  metabolic  panel,  urine  ketones, 
glycosylated hemoglobin, and C-peptide. 
<0000> 
Hypophysitis: 
o 
For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or less, 
steroid taper should be started and continued over no less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered. 
o 
For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate hormones 
may be required as the steroid dose is tapered. 
<0000> 
Hyperthyroidism or Hypothyroidism: 
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. 
 
o 
Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism): 
 
In hyperthyroidism, non-selective beta-blockers (e.g. propranolol) are suggested 
as initial therapy. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 37
 
 
 
In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothyroinine, is indicated per standard of care. 
o 
Grade 3-4 hyperthyroidism 
 
Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks. Replacement of appropriate hormones may 
be required as the steroid dose is tapered. 
<0000> 
Hepatic: 
o 
For Grade 2 events, monitor liver function tests more frequently until returned to baseline 
values (consider weekly). 
 
Treat with IV or oral corticosteroids 
o 
For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
o 
When  symptoms  improve  to  Grade  1  or  less,  a  steroid  taper  should  be  started  and 
continued over no less than 4 weeks. 
<0000> 
Renal Failure or Nephritis: 
o For Grade 2 events, treat with corticosteroids. 
o For Grade 3-4 events, treat with systemic corticosteroids. 
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks. 
<0000> 
Management of Infusion Reactions: Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of completion of infusion. 
 
 
Table below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK-3475). 
 
T A B L E 1 INFUSION REACTION TREATMENT GUIDELINES 
 
 
 
NCI CTCAE Grade 
Treatment 
Premedication at subsequent 
dosing 
Grade 1 
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator. 
None 
Grade 2 
Requires infusion interruption but 
responds promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated 
for < =24 hrs 
Stop Infusion and monitor symptoms. 
Additional appropriate medical therapy may 
include but is not limited to: 
IV fluids 
Antihistamines 
NSAIDS 
Acetaminophen 
Narcotics 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator. 
Subject may be premedicated 
1.5h (± 30 minutes) prior to 
infusion of pembrolizumab (MK- 
3475) with: 
 
Diphenhydramine 50 mg po (or 
equivalent dose of 
antihistamine). 
 
Acetaminophen 500-1000 mg po 
(or equivalent dose of 
antipyretic). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 38
 
 
NCI CTCAE Grade 
Treatment 
Premedication at subsequent 
dosing 
 
If symptoms resolve within one hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate 
(e.g., from 100 mL/hr to 50 mL/hr). 
Otherwise dosing will be held until symptoms 
resolve and the subject should be 
premedicated for the next scheduled dose. 
Subjects who develop Grade 2 toxicity 
despite adequate premedication should be 
permanently discontinued from further 
trial treatment administration. 
 
Grades 3 or 4 
 
Grade 3: 
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); recurrence 
of symptoms following initial 
improvement; hospitalization 
indicated for other clinical sequelae 
(e.g., renal impairment, pulmonary 
infiltrates) 
 
Grade 4: 
Life-threatening; pressor or 
ventilatory support indicated 
Stop Infusion. 
Additional appropriate medical therapy may 
include but is not limited to: 
IV fluids 
Antihistamines 
NSAIDS 
Acetaminophen 
Narcotics 
Oxygen 
Pressors 
Corticosteroids 
Epinephrine 
 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator. 
Hospitalization may be indicated. 
Subject is permanently discontinued from 
further trial treatment administration. 
No subsequent dosing 
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of 
drug administration. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 39
 
6 STUDY PROCEDURES AND OBSERVATIONS 
6.1 SCHEDULE OF PROCEDURES AND OBSERVATIONS 
The study-specific assessments are detailed in this section and outlined in Table 4 Schedule of Study 
Procedures. Screening assessments must be performed within 28 days prior to the first dose of 
investigational product unless otherwise noted (biopsy samples during screening may be done 90 days 
prior to the first dose of treatment, or at the discretion of the study sponsor). Any results falling outside 
of the reference ranges may be repeated at the discretion of the Investigator. All on-study visit 
procedures are allowed a window of ± 2 days unless otherwise noted.  Treatment or visit delays for 
public holidays or weather conditions do not constitute a protocol violation. Research-related 
biomaterials will no longer be collected/processed for patients who continue treatment beyond 24 
months. 
A written, signed, informed consent form (ICF) and a Health Insurance Portability and Accountability Act 
(HIPAA) authorization must be obtained before any study-specific assessments are initiated. A copy of 
the signed ICF will be given to the subject and a copy will be filed in the medical record. The original will 
be kept on file with the study records. Informed consent for specimens for Future Biomedical Research 
will be obtained during screening and must be obtained prior to collection of all Future Biomedical 
Research specimens. 
All patients who are consented will be registered in OnCore®, the UCSF Helen Diller Family 
Comprehensive Cancer Center Clinical Trial Management System (CTMS).  Data will be captured in 
Medidata or on paper case report forms (CRFs) maintained by the site. Data may be captured on paper 
CRFs for patients who continue treatment beyond 24 months. Both systems are password protected and 
meet HIPAA requirements. 
 
6.1.1 PRETREATMENT PERIOD 
6.1.1.1 Screening Assessments 
The Screening procedures and assessments must be completed within 28 days of the Day 1 Visit unless 
otherwise noted. 
• 
Baseline conditions assessment 
• 
Baseline medications taken within 28 days of Cycle 1 
• 
Archival tissue collection 
• 
BRAF status 
• 
Physical exam 
• 
Vital signs, including: 
• 
blood pressure  (systolic and diastolic),  respiratory rate,  heart rate, temperature, 
height, and weight 
• 
Complete medical history including history of prior treatments and any residual toxicity relating 
to prior treatment 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 40
 
 
• 
Documentation of disease staging 
• 
Documentation of disease evaluation by RECIST v1.1 
• 
Photograph assessment with a ruler and bi-dimensional clinical measurements of target and non- 
target lesions. Photographs and measurements should be performed prior to biopsies. 
• 
Performance status (ECOG) 
• 
Two newly obtained biopsies are mandatory at baseline. One biopsy will be used for 
evaluation of TIL score by flow cytometry.  A valid flow cytometry result is not required for study 
participation, but repeated biopsy for reanalysis is strongly recommended for patient with insufficient 
TILs in the first tissue sample. Low TIL samples will be presumed to have a low proportion of partially 
exhausted T cells for reporting purposes unless a second sample reveals an adequate TIL population. The 
second biopsy will be fixed in formalin and used for biomarker analysis in the tumor microenvironment 
using at least one IHC-based assay. Archival tissue should also be collected whenever                       
available and as long as tissue has not been previously irradiated and no systemic antineoplastic therapy 
has been received by the patient between the time of the biopsy and the first administration of protocol 
therapy. Coagulation assessment must be evaluated within 24 hrs prior to all biopsy collections. Biopsy 
samples may be collected up to 90 days prior to the first dose of treatment, or at the discretion of the 
study sponsor. 
• 
Complete blood count (CBC) with differential, including: hemoglobin, platelets, red blood cells, 
white blood cells, basophils (abs), eosinophils (abs), lymphocytes (abs), monocytes (abs), neutrophils 
(abs), hematocrit 
• 
Blood chemistry assessment, including: sodium, potassium, chloride, calcium, phosphorus, 
magnesium, carbon dioxide CO2 or bicarbonate, urea nitrogen (BUN), creatinine, uric acid, total 
protein, albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), direct bilirubin, non-fasting glucose. 
• 
Coagulation assessment, including: prothrombin time, partial thromboplastin time,  and 
international normalized ratio (PT/PTT/INR) 
• 
Thyroid function tests, including: thyroid-stimulating hormone (TSH), free thyroxine (FT4), T3 
• 
Serum HIV and Hepatitis assessment, including: HIV 1/2 antibodies, Hepatitis B surface antigen 
(HBsAg), Hepatitis C virus RNA (qualitative). 
• 
Serum or urine pregnancy test within 14 days prior to the start of study drug 
• 
Urinalysis (dipstick and microscopic examination when findings are abnormal) 
• 
Imaging (CT or PET-CT or MRI) of chest, abdomen and pelvis (and all extremities with lesions) 
for tumor/lesion assessment 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 41
 
6.1.2 TREATMENT PERIOD 
6.1.2.1 
Study Procedures, Cycle 1, Day 1 
 
Physical Exam, ECOG, weight, complete CBC with differential, blood chemistry, and urinalysis do not 
need to be repeated if screening evaluations performed within 7 days of C1D1 unless a clinically 
significant change is suspected 
• 
EP of intratumoral pIL-12: The majority of patients experience transient pain with 
electroporation that usually resolves within 5min of the treatment. 
• 
pIL-12 EP. Intratumoral pIL-12 should be given first followed by a minimum  of  60 minutes 
observation prior to pembrolizumab 
• 
Infusion of pembrolizumab 
• 
Review of concomitant medications since last visit 
• 
Symptom-directed physical examination 
• 
Vital signs, including: blood pressure (systolic and diastolic), respiratory rate, heart rate 
temperature, and weight 
• 
Performance status 
• 
Complete blood count (CBC) with differential, including: hemoglobin, platelets, red blood cells, 
white blood cells, basophils (abs), eosinophils (abs), lymphocytes (abs), monocytes (abs), 
neutrophils (abs), and hematocrit 
• 
Blood chemistry assessment, including: sodium, potassium, chloride, calcium, phosphorus, 
magnesium, carbon dioxide CO2 or bicarbonate, urea nitrogen (BUN), creatinine, uric acid, total 
protein, albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), direct bilirubin, non-fasting glucose 
• 
Exploratory research blood 
• 
Research blood for future biomedical research 
• 
Urinalysis (dipstick and microscopic examination when findings are abnormal) 
6.1.2.2 Study Procedures Cycle 1, Day 5 and Day 8 
• 
Evaluation of adverse events including pain assessment (conducted right before intratumoral 
pIL-12-EP, immediately following pIL-12 EP and approximately 5 minutes after pIL-12 EP using a 
0-10 numeric pain rating scale) 
• 
Review of concomitant medications since last visit 
• 
Vital signs, including: blood pressure (systolic and diastolic), respiratory rate, heart rate, and 
temperature 
• 
Exploratory research blood (Day 8 only) 
• 
Research blood for future biomedical research (Day 8 only) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 42
 
6.1.2.3 Study Procedures Cycle 2, Day 1 (and Even Cycles) 
<0000> 
Infusion of pembrolizumab 
• 
Evaluation of adverse events 
• 
Review of concomitant medications since last visit 
• 
Symptom-directed physical examination 
• 
Vital signs, including: blood pressure (systolic  and diastolic), respiratory rate,  heart rate, 
temperature, weight 
• 
Performance status 
• 
Prior to treatment, a biopsy from both a treated and untreated lesion must be obtained for 
biomarker analysis (Cycle 2 Only). A biopsy of the changing lesion(s) should be obtained for 
biomarker analysis, ideally at first sign of tumor change. Coagulation assessment must be 
evaluated within 24 hours prior to all biopsy collections 
• 
Complete blood count (CBC) with differential, including: hemoglobin, platelets, red blood cells, 
white blood cells, basophils (abs), eosinophils (abs), lymphocytes (abs), monocytes (abs), 
neutrophils (abs), and hematocrit 
• 
Blood chemistry assessment, including: sodium, potassium, chloride, calcium, phosphorus, 
magnesium, carbon dioxide CO2 or bicarbonate), urea nitrogen (BUN), creatinine, uric acid, total 
protein, albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), direct bilirubin, non-fasting glucose. 
• 
Coagulation assessment is only required if a biopsy is planned and should be within 24 hours 
prior to the procedure. The coagulation assessment includes: prothrombin  time, 
partial 
thromboplastin time,   international 
normalized ratio (PT/PTT/INR) 
• 
Thyroid function tests, including: thyroid-stimulating hormone (TSH), free thyroxine (FT4), T3 
• 
Exploratory research blood (through 24 months of treatment) 
• 
Research blood for future biomedical research (through 24 months of treatment) 
• 
Urinalysis (dipstick and microscopic examination when findings are abnormal) 
• 
6.1.2.4 Study Procedures Cycle 3, Day 1 (and Odd Cycles) 
• 
pIL-12-EP: Intratumoral pIL-12 should be given first followed by a minimum 60 minutes 
observation prior to pembrolizumab 
• 
The majority of patients experience transient pain with electroporation that usually resolves 
usually within 5min of the treatment. 
• 
Infusion of pembrolizumab 
• 
Review of concomitant medications since last visit 
• 
Symptom-directed physical examination 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 43
 
 
• 
Vital signs, including: blood pressure (systolic and diastolic), respiratory rate, heart rate, 
temperature, weight 
• 
Performance status 
• 
A biopsy of  the changing lesion(s) should be obtained for biomarker analysis. 
• 
Coagulation assessment must be evaluated within 24 hours prior to all biopsy collections. 
• 
Complete blood count (CBC) with differential, including: hemoglobin, platelets, red blood cells, white 
blood cells, basophils (abs), eosinophils (abs), lymphocytes (abs), monocytes (abs), neutrophils 
(abs), and hematocrit 
• 
Blood chemistry assessment, including: sodium, potassium, chloride, calcium, phosphorus, 
magnesium, carbon dioxide CO2 or bicarbonate, urea nitrogen (BUN), creatinine, uric acid, total 
protein, albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), direct bilirubin, non-fasting glucose. 
• 
Exploratory research blood (through 24 months of treatment) 
• 
Research blood for Future Biomedical Research (through 24 months of treatment) 
• 
Urinalysis (dipstick and microscopic examination when findings are abnormal) 
• 
Photograph documentation with a ruler and bi-dimensional clinical measurements of target and 
non-target lesions. Photographs and measurements should be performed prior to any planned 
biopsies. (every 4 cycles - within 7 days prior of Cycle) 
• 
Documentation of disease evaluation by RECIST v1.1 (every 4 cycles - within 7 days prior of   
Cycle) 
• 
Imaging (CT or PET-CT or MRI) of chest, abdomen and pelvis (and all extremities with lesions) 
for tumor/lesion assessment (every 4 cycles - within 7 days prior of Cycle). . 
 
 
6.1.2.5 Study Procedures Cycle 3 (and Odd Cycles), Day 5 and Day 8 
• 
pIL-12 EP 
• 
The majority of patients experience pain with electroporation that is transient and resolves 
usually within 5min of the treatment. 
• 
Review of concomitant medications since last visit 
• 
Vital signs, including: blood pressure (systolic and diastolic), respiratory rate, heart rate, 
temperature 
• 
Exploratory research blood (Day 8 only, through 24 months of treatment) 
• 
Research blood for Future Biomedical Research (Day 8 only, through 24 months of treatment) 
 
 
6.1.3 SAFETY FOLLOW-UP/END OF STUDY VISIT STUDY PROCEDURES 
To be completed within 30 days +/- 2 days of the last dose of study drug. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 44
 
 
• 
Evaluation of adverse events 
• 
Review of concomitant medications since last visit 
• 
Complete physical examination 
• 
Vital signs, including: blood pressure (systolic and diastolic), respiratory rate, heart rate, 
temperature, weight 
• 
Performance status 
• 
Complete blood count (CBC) with differential, including: hemoglobin, platelets, red blood cells, 
white blood cells, basophils (abs), eosinophils (abs), lymphocytes (abs), monocytes (abs), 
neutrophils (abs), hematocrit 
• 
Blood chemistry assessment, including: sodium, potassium, chloride, calcium, phosphorus, 
magnesium, carbon dioxide CO2 or bicarbonate), urea nitrogen (BUN), creatinine, uric acid, total 
protein, albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), direct bilirubin, non-fasting glucose. 
• 
Coagulation assessment is only required if a biopsy is planned and should be within 24 hours of 
the procedure. The coagulation assessment includes: prothrombin  time, 
partial 
thromboplastin time,   international 
normalized 
ratio (PT/PTT/INR) 
• 
Thyroid function tests, including: thyroid-stimulating hormone (TSH), free thyroxine (FT4), T3 
• 
Urinalysis (dipstick and microscopic examination when findings are abnormal) 
• 
Photograph documentation with a ruler and bi-dimensional clinical measurements of target and 
non-target lesions. Photographs and measurements are to be performed prior to any planned 
biopsies. 
• 
Imaging (CT or PET-CT or MRI) of chest, abdomen and pelvis (and all extremities with lesions) 
for tumor/lesion assessment 
• 
Documentation of disease evaluation by RECIST v1.1 
 
 
If visit occurs within the 24 months on trial: 
• 
A biopsy of changing lesion(s) should be obtained for biomarker analysis. If a patient 
discontinues for reasons other than progression, a biopsy of a malignant lesion should be 
obtained. Coagulation assessment must be evaluated within 24 hours prior to all biopsy 
collections. 
• 
Exploratory research blood 
• 
Research blood for future biomedical research 
6.1.4 POST-TREATMENT/SURVIVAL FOLLOW-UP PROCEDURES 
Upon completion of Safety Follow-up, all patients will enter the Survival Follow-up Phase unless they 
withdraw consent for further data collection. For subjects who discontinue for reasons other than 
progressive disease, every attempt should be made to continue monitoring their disease status by 
radiologic imaging. Radiologic monitoring should continue (1) until start of a new anti- cancer treatment, 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 45
 
 
(2) until documented disease progression, or (3) until death, whichever occurs first. Radiographic 
imaging in follow-up may be performed as clinically indicated or per local standard of care. At time of off 
treatment, all patients will enter survival follow-up, and patients or their caregivers will be contacted 
approximately every 90 days until closure of the study via a site-placed telephone call or documentation 
of clinic visit. Inquiries into the following will be made: 
• 
Date of first progression (if the first progression has not occurred prior to entry in the Follow-Up 
Phase) 
• 
Follow-up therapy for the treatment of melanoma (including radiation, anticancer treatment, 
adjuvant therapies or surgeries) 
• 
Resolution of AEs and SAEs ongoing at the time of entry into survival follow-up 
• 
Status (alive, no evidence of disease, alive with disease, deceased) 
• 
Cause and date of death (if applicable) 
 
 
6.1.5 DISCONTINUATION OF THERAPY 
The Investigator will withdraw a patient whenever continued participation is no longer in the patient’s 
best interests.  Reasons for withdrawing a patient include, but are not limited to, disease progression, 
the occurrence of an adverse event or a concurrent illness, a patient’s request to end participation, a 
patient’s non-compliance or simply significant uncertainty on the part of the Investigator that continued 
participation is prudent. There may also be administrative reasons to terminate participation, such as 
concern about a patient’s compliance with the prescribed treatment regimen. 
 
 
6.1.6 WITHDRAWAL/DISCONTINUATION 
When a subject discontinues/withdraws prior to trial completion, all applicable activities scheduled for 
the final trial visit should be performed at the time of discontinuation. Any adverse events which are 
present at the time of discontinuation/withdrawal should be followed in accordance with the safety 
requirements outlined in Section 7.4 – Follow-up of Adverse Events. Subjects who a) attain a CR or b) 
complete 24 months of treatment with pembrolizumab may discontinue treatment with the option of 
restarting treatment if they meet the criteria specified in Section 5.1.2. After discontinuing treatment 
following assessment of CR, these subjects should return to the site for a Safety Follow-up Visit 
(described in Section 6.1.3) and then proceed to the Follow-Up Period of the study (described in Section 
6.1.4). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 46
 
 
Table 4 Schedule of Study Procedures 
 
 
Period/Procedure 
 
Screening 
 
Cycle 1 (21 days ±3) 
Cycle 2 and 
Even Cycles 
(21 days ±3) 
Cycle 3 and Odd Cycles (21 
days ±3) 
Safety 
Follow-Up/ End 
of Study Visit 
 
Study Day/Visit Day 
 
-28 to 0 
 
1 
 
5 
 
8 
 
1 
 
1 
 
5 
 
8 
Within 30 days from Last 
Dose 
Informed consent 
X 
 
 
 
 
 
 
 
 
Baseline conditions 1 
X 
 
 
 
 
 
 
 
 
AE assessment 
 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant 
medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Archival Specimen 
Collection 
X 
 
 
 
 
 
 
 
 
BRAF Status 
X 
 
 
 
 
 
 
 
 
Treatment/Drug 
Administration 
Pembrolizumab 
 
X 
 
 
X 
X 
 
 
 
pIL-12 EP 
 
X 
X 
X 
 
X 
X 
X 
 
Pain Assessment2 
 
X 
X 
X 
 
X 
X 
X 
 
Clinical procedures 
 
 
 
Physical exam20 
X 
X 
 
 
X 
X 
 
 
X 
Vital signs3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Medical history4 
X 
 
 
 
 
 
 
 
 
Disease staging 5 
X 
 
 
 
 
 
 
 
 
Disease Evaluation by 
RECIST v1.16 
X 
 
 
 
 
X6 
 
 
X6 
Performance status7 
X 
X 
 
 
X 
X 
 
 
X 
Biopsy8 
X8 
 
 
 
X8 
X8 
 
 
X8 
Lesion Photographs 
and bi-dimensional 
clinical measurements 
 
X19 
 
 
 
 
 
X19 
 
 
 
X19 
Laboratory 
procedure 
CBC w/ Diff 9 
X 
X 
 
 
X 
X 
 
 
X 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 47
 
 
Blood chemistry 10 
X 
X 
 
 
X 
X 
 
 
X 
Coagulation 
X 
 
 
 
X11 
X11 
X11 
X11 
X11 
Thyroid Function12 
X 
 
 
 
X12 
 
 
 
X 
HIV,  Hepatitis  B  and 
C13 
X 
 
 
 
 
 
 
 
 
Pregnancy test (serum 
or urine)14 
X 
 
 
 
 
 
 
 
 
Exploratory   Research 
Blood15 
 
 
X 
 
 
X 
X21 
X21 
 
X21 
X21 
Research 
Blood 
for 
Future 
Biomedical 
Research15 
 
 
X 
 
 
X 
 
X21 
 
X21 
 
 
X21 
 
X21 
Urinalysis16 
X 
X 
 
 
X16 
X16 
 
 
X 
Imaging procedures 
Imaging 
X17 
 
 
 
 
X17 
 
 
X17, 18 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 48
 
 
 
1. 
Baseline conditions assessment per DSMC policy (Baseline Conditions VI Form). This will only be required 
for patients enrolled and treated at UCSF. For other participating sites, baseline conditions will be 
recorded and included as part of the medical history. 
2. 
Pain assessment monitoring will be performed as part of the adverse events assessment on Days 1, 5 and 
8 of each pIL-12 EP treatment visit. Patients will use a numeric pain rating scale to rate their pain with a 
start and stop time to capture any pain associated with EP procedure and duration. Any pain five minutes 
after the EP treatment will be evaluated on the pain scale and documented as an AE. 
3. 
Includes blood pressure (systolic and diastolic), respiratory rate, heart rate and temperature. Height only 
required at screening. Weight collected only at screening, Day 1 of every cycle, and at the Safety Follow- 
up/End of Study visit. 
4. 
Medical history all cancer history and includes any conditions resolved within 6 months of enrollment as 
well as surgeries and therapies related to the treatment of melanoma and any residual toxicity. 
5. 
Disease-specific staging criteria. 
6. 
Disease will be followed using criteria defined by RECIST v1.1. Evaluation only required at time of imaging 
therefore will be done every 4 cycles (within 7 days prior to Cycle 5, 9, 13, etc). 
7. 
ECOG. 
8. 
Two newly obtained biopsies are mandatory at baseline. 
Screening biopsy samples may be collected up to 30 days prior to the first dose of treatment, or at the 
discretion of the study sponsor. 
One biopsy will be used for evaluation of TIL score by flow cytometry and analysis. A valid flow cytometry 
result is not required for study participation, but repeated biopsy for reanalysis is strongly recommended 
for patient with insufficient TILs in the first tissue sample. Low TIL samples will be presumed to have a low 
proportion of partially exhausted T cells for reporting purposes unless a second sample reveals an adequate 
TIL population. 
The second biopsy will be fixed in formalin and used for  biomarker analysis to confirm low PD-L1 
expression in the tumor microenvironment using Merck’s PD-L1 IHC assay (clone 22C3). 
At Cycle 2, prior to treatment, biopsies from both a treated and untreated lesion must be obtained for 
biomarker analysis. Biopsies of changing lesions should be obtained at sign of regression or progression for 
biomarker analysis. The biopsy techniques allowed in the study include tru cut core biopsies or surgical 
biopsies. Coagulation assessment must be evaluated within 24 hrs prior to all biopsy collections. 
Archival tissue may be utilized for the Merck PD-L1 assay as long as tissue has not been previously 
irradiated and no systemic antineoplastic therapy has been received by the patient between the time of the 
biopsy and the first administration of protocol therapy. However, two newly obtained biopsies at baseline 
are still required. 
Post-treatment biopsy should not be performed if End of Study visit occurs more than 24 months from 
initiation of study treatment. 
Unless noted by the PI no other biopsies are required. 
9. 
Including hemoglobin, platelets, red blood cells, white blood cells, basophils (abs), eosinophils (abs), 
lymphocytes (abs), monocytes (abs), neutrophils (abs), and hematocrit. 
10. Including sodium, potassium, chloride, calcium, phosphorus, magnesium, carbon dioxide CO2 or 
bicarbonate), urea nitrogen (BUN), creatinine, uric acid, total protein, albumin, total bilirubin, alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase 
(LDH), direct bilirubin, non-fasting glucose. 
11. Including  PT/INR  and  aPTT.  Coagulation  assessment  required  if  biopsies  are  planned  and  must  be 
evaluated within 24 hrs prior to all biopsy collections, including the biopsy at Cycle 2. 
12. Including T3, FT4 and TSH. Following Cycle 2, testing will be performed every other cycle (i.e., even cycles), 
13. Including HIV 1/2 antibodies, HBsAg, HCV RNA (qualitative). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 49
 
 
14. Only required for women of child-bearing potential (i.e., postmenopausal women and women who have had 
a hysterectomy, oophorectomy are not of child- bearing potential). Negative test must be performed within 
14 days prior to first study treatment. 
15. Whole blood collection for biomarker analysis. Research tubes should be collected prior to treatment. 
16. Including dipstick and microscopic examinations when findings are abnormal. Following Cycle 1, testing 
will be performed every 3 cycles (e.g., Cycle 4, 7, 10, 13, etc.). 
17. Tumor imaging (either CT or PET-CT or MRI, with strong preference for CT) will be performed within 28 
days prior to enrollment. CT must be of the chest, abdomen and pelvis (and all extremities with lesions). 
The same imaging technique has to be used in a patient throughout the study. Imaging performed every 4 
cycles, thus imaging should be performed within 7 days prior to Cycle 5, Cycle 9, Cycle 13, etc.). After first 
documentation of response, repeat imaging is required approximately 4 weeks later for confirmation of CR 
and PR. 
18. The same imaging technique should be used in a patient as used earlier in the study. Assessment to be 
performed in patients who discontinue study therapy early without documented disease progression. 
Every effort should be made to continue monitoring their disease status by radiologic imaging. Monitoring 
should continue 1) until start of a new anti-cancer treatment, (2) until documented disease progression, or 
(3) until death, whichever occurs first. Radiographic imaging in follow-up may be performed as clinically 
indicated or per local standard of care. 
19. Photograph documentation with a ruler and bi-dimensional clinical measurements of target and non-target 
lesions will be performed at screening, then every 4 cycles.. Photographs and clinical measurements are to 
be completed prior to any planned biopsies. After first documentation of response, repeat assessment is 
required approximately 4 weeks later for confirmation for CR and PR. 
20. Screening and Safety Follow-Up/End of Study Visits should include a complete physical exam. Physical 
Exams at all other study time points should be symptom-directed. 
21. Blood will only be collected for research through 24 months on study. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 50
 
 
6.1.7 CRITERIA FOR PAIN ASSESSMENT FOR AE REPORTING 
 
 
For patients who experience pain, record start and stop time on the CRF. If pain persists beyond 5 
minutes, the duration of time required for patient’s post-treatment pain score to return to their 
baseline should be captured as an AE for pain, assessing the rating and duration (Figure 2). 
 
 
Figure 2 Numeric pain rating scale 
 
 
 
 
 
6.2 GUIDELINES FOR BIOPSY COLLECTION 
Fresh tumor biopsies will be collected prior to first treatment with pIL-12-EP and at multiple time 
points post-treatment. Tumors biopsied at post-treatment time points may be obtained from either 
treated or untreated tumors as detailed below. Whenever possible, and without the risk of artifact from 
the screening biopsy, one of the post-treatment biopsies should be obtained from the same lesion 
biopsied during screening. Tumors selected for biopsy must be accessible and the procedure 
considered safe per the investigator. At any time point where a biopsy is required but the patient 
does not present with an accessible tumor or if a biopsy of adequate size to meet all exploratory 
objectives cannot be safely obtained (i.e. patient has no lesions to biopsy), this does not constitute 
a protocol deviation but should be clearly documented in the patient’s record. The following 
guidance is provided for each biopsy time point: 
 
 
Screening: 
• 
Two biopsies (5mm punch, core or excisional biopsy) are required. A re-biopsy is permitted if 
results are indeterminate. Whenever possible, the second biopsy should come from the largest 
accessible lesion to allow for a second biopsy at Cycle 2. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 51
 
 
Prior to Treatment Cycle 2, Day 1: 
• 
Biopsies of both an untreated lesion and a treated lesion are required (5mm punch, core or 
excisional biopsy). Whenever possible, one of these biopsies should be from the same lesion as the 
screening biopsy if the lesion is of adequate size such that the margins of a repeat biopsy would not 
intersect with the margins of previous biopsy. If either lesion is too small for 5mm biopsy, please 
contact the investigator- sponsor. 
 
 
At Safety Follow-up/ End of Study Visit 
• 
Biopsies should be at the EOS visit whenever feasible. 
<0000> 
Biopsy should not be performed if EOS visit occurs more than 24 months from initiation of 
study treatment. 
 
 
6.3 CONCOMITANT MEDICATIONS/VACCINATIONS (ALLOWED & PROHIBITED) 
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the 
ongoing trial. If there is a clinical indication for one of these or other medications or vaccinations 
specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be 
required. The Investigator should discuss any questions regarding this with the Sponsor-Principal 
Investigator. The final decision on any supportive therapy or vaccination rests with the Investigator 
and/or the subject's primary physician. However, the decision to continue the subject on trial therapy 
or vaccination schedule requires the mutual agreement of the Investigator, the Sponsor-Principal 
Investigator, and the subject. 
6.3.1 ACCEPTABLE CONCOMITANT MEDICATIONS 
All treatments that the Investigator considers necessary for a subject’s welfare may be administered at 
the discretion of the Investigator in keeping with the community standards of medical care. All 
concomitant medication will be recorded on the case report form (CRF) including all prescription, 
over-the-counter (OTC), herbal supplements, and IV medications and fluids. If changes occur during 
the trial period, documentation of drug dosage, frequency, route, and date may also be included on the 
CRF. 
All concomitant medications received within 28 days before the first dose of trial treatment and 30 
days after the last dose of trial treatment should be recorded. Concomitant medications administered 
after 30 days after the last dose of trial treatment should be recorded for SAEs and ECIs. 
6.3.2 PROHIBITED CONCOMITANT MEDICATIONS 
Subjects  are prohibited from  receiving the  following therapies  during the Screening and 
Treatment Phase (including retreatment for post-complete response relapse) of this trial: 
• 
Anti-cancer systemic chemotherapy or biological therapy 
• 
Immunotherapy not specified in this protocol 
• 
Chemotherapy not specified in this protocol 
• 
Investigational agents other than pembrolizumab and pIL-12 EP 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 52
 
 
• 
Radiation therapy 
o 
Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be 
allowed after consultation with Sponsor-Principal Investigator. 
• 
Live vaccines  within 30 days  prior to the first dose of  trial treatment and while 
participating in the trial. Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) 
vaccine.  Seasonal influenza vaccines for injection are generally killed virus vaccines and are 
allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, 
and are not allowed. 
• 
Glucocorticoids for any purpose other than to modulate symptoms from an event of clinical 
interest of suspected immunologic etiology. The use of physiologic doses of corticosteroids 
may be approved after consultation with the Sponsor-Principal Investigator. Topical steroids 
are permitted. 
Subjects who, in the assessment by the Investigator, require the use of any of the aforementioned 
treatments for clinical management should be removed from the trial. Subjects may receive other 
medications that the Investigator deems to be medically necessary. 
The Exclusion Criteria describes other medications which are prohibited in this trial (described in 
Section 3.3.2). There are no prohibited therapies during the Post-Treatment Follow-up Phase. 
 
 
6.4 DIETARY RESTRICTIONS 
Patients should maintain a normal, healthy diet. 
 
 
6.5 CONTRACEPTION 
Pembrolizumab and/or pIL-12 EP may have adverse effects on a fetus in utero. Furthermore, it is  not 
known if pembrolizumab and/or pIL-12 EP has  transient adverse effects on the composition of 
sperm. Non-pregnant, non-breast-feeding women may be enrolled if they are willing to use 2 methods 
of birth control or are considered highly unlikely to conceive.  Highly unlikely to conceive is defined as 
1) surgically sterilized, or 2) postmenopausal (a woman who is≥45 years of age and has not had 
menses for greater than 1 year will be considered postmenopausal), or 3) not heterosexually active for 
the duration of the study. The two birth control methods can be either two barrier methods or a 
barrier method plus a hormonal method to prevent pregnancy. Subjects should start using birth 
control from signing of  consent throughout the study period up to 120 days after the last dose of 
study therapy. 
The following are considered adequate barrier methods of contraception: diaphragm, condom (by the 
partner), copper intrauterine device, sponge, or spermicide. Appropriate hormonal contraceptives 
will include any registered and marketed contraceptive agent that contains an estrogen and/or a 
progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents). 
Subjects should be informed that taking the study medication may involve unknown risks to the fetus 
(unborn baby) if pregnancy were to occur during the study. In order to participate in the study they 
must adhere to the contraception requirement (described above) for the duration of the study and 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 53
 
 
during the follow-up period defined above. Reporting of Pregnancy and Lactation to the Sponsor- 
Principal Investigator and to Merck and OncoSec Medical Inc. is required. If there is any question that 
a subject will not reliably comply with the requirements for contraception, that subject should not be 
entered into the study. 
 
 
6.5.1 USE IN PREGNANCY 
If a subject inadvertently becomes pregnant while on treatment with pembrolizumab and/or pIL-12 
EP, the subject will immediately be removed from the study. The site will contact the subject at least 
monthly and document the subject’s status until the pregnancy has been completed or terminated. 
The outcome of  the pregnancy will be reported to the  Sponsor-Principal Investigator (or 
designee) without delay and within 24 hours if the outcome is a serious adverse experience (e.g., 
death, abortion, congenital anomaly, or other disabling or life-threatening complication to the mother 
or newborn). The study Investigator will make every effort to obtain permission to follow the 
outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor-Principal 
Investigator. 
If a male subject impregnates his female partner the study personnel at the site must 
be informed immediately and the pregnancy reported to the Sponsor-Principal Investigator (or 
designee) and followed as described above. 
6.5.2 USE IN NURSING WOMEN 
It is unknown whether pembrolizumab and/or pIL-12 is excreted in human milk. Since many drugs 
are excreted in human milk, and because of the potential for serious adverse reactions in the nursing 
infant, subjects who are breast-feeding are not eligible for enrollment. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 54
 
 
7 REPORTING AND DOCUMENTATION OF RESULTS 
7.1 EVALUATION OF EFFICACY (OR ACTIVITY) 
7.1.1 ANTITUMOR EFFECT – SOLID TUMORS 
Response and progression in this study will be evaluated using the new international criteria proposed 
by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. 
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in 
the RECIST v1.1 criteria. Evaluation by immune-related Response Criteria (irRC) to satisfy secondary 
objectives is described in Section 7.1.2. 
 
7.1.1.1 Definitions 
Evaluable for toxicity (i.e., Safety Evaluable Population) 
All patients will be evaluable for toxicity from the time of their first treatment with the study drug. 
Evaluable for objective response (i.e., Efficacy Evaluable Population) 
Only those patients who have measurable disease present at baseline, have received at least one cycle 
of therapy of both pembrolizumab and pIL-12 EP will be considered evaluable for response.  These 
patients will have their response classified according to the definitions stated below. 
 
 
7.1.1.2 Disease Parameters 
Measurable disease 
Measurable disease is defined as lesions (or tumors) that can be accurately measured in at least one 
dimension (longest diameter to be recorded) with a minimum size of 15mm by CT scan (irrespective 
of scanner type), 10mm caliper measurement by clinical exam (when superficial), and/or 20mm by 
chest X-ray (if clearly defined and surrounded by aerated lung). 
All tumor measurements will be recorded in millimeters or decimal fractions of centimeters. 
Previously irradiated lesions are considered non-measurable except in cases of documented 
progression of the lesion since the completion of radiation therapy. It is recommended that previously 
irradiated lesions that would  otherwise be considered measurable be followed closely by 
investigators comments, measurements and photographs if applicable for retrospective review. 
Target lesions 
All measurable lesions up to a maximum of 5 lesions total (and a maximum of two lesions per organ) 
representative of all involved organs should be identified as target lesions and recorded and measured 
at baseline.  Target lesions will be selected on the basis of their size (lesions with the longest diameter)  
and their suitability for accurate  repeated measurements (either by imaging techniques or 
clinically). A sum of the longest diameter (LD) for all target lesions will be calculated and reported      
as the baseline sum LD.  The baseline sum LD will be used as reference by which to characterize the 
objective tumor response. 
Non-target lesions 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 55
 
 
All other lesions (or sites of disease) including any measurable lesions over and above the 5 target 
lesions should be identified as  non-target lesions and should also be recorded at baseline.  It is 
possible to record multiple non-target lesions involving the same organ as a single item on the case 
record form (e.g. “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”).  Bone lesions 
may be measureable if ≥ 1 cm on MRI. 
Measurements of these lesions are not required, but the 
presence or absence of each will be noted throughout follow-up. It is  recommended that bone 
lesions  be followed closely by investigators  by comments and measurements whenever possible for 
retrospective review. 
 
 
Non-measurable disease 
Non-measurable disease is  all  other lesions  (or sites  of disease), including small  lesions (longest 
diameter < 20 mm with conventional techniques or < 10 mm using spiral CT scan). Leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques are all non- measurable. 
 
 
7.1.1.3 Methods for Evaluation of Measurable Disease 
All measurements will be taken and recorded in metric notation using a ruler or calipers. All baseline 
evaluations will be performed as closely as possible to the beginning of treatment and never more 
than 28 days before the beginning of the treatment. 
The same method of assessment and the same technique will be used to characterize each identified 
and reported lesion at baseline and during follow-up. Imaging-based evaluation is preferred to 
evaluation by clinical examination when both methods have been used to assess the antitumor effect 
of a treatment. 
Conventional CT (or PET-CT) 
These techniques  should be performed with cuts of 10 mm  or less  in slice thickness 
contiguously. Spiral CT should be performed using a 5 mm contiguous reconstruction algorithm. This 
applies to tumors of the chest, abdomen, and pelvis. If measurable disease is noted in other areas of 
the body, CT imaging of those areas should be performed as well. Whole-body PET-CT is the preferred 
imaging technique whenever possible. 
 
7.1.1.4 RECIST v1.1 Response Criteria 
Evaluation of Target Lesions 
Complete Response (CR) 
Disappearance of all target lesions, determined by two separate observations conducted not 
less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must 
have reduction in short axis to <10 mm (the sum may not be “0” if there are target nodes). 
There can be no appearance of new lesions. 
Partial Response (PR) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 56
 
 
At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as 
reference the baseline sum LD. There can be no appearance of new lesions. 
Progressive Disease (PD) 
At least a 20% increase in the sum of the SLD of target lesions, taking as reference the smallest 
sum SLD recorded since the treatment started and minimum 5 mm increase over the nadir, or 
the appearance of one or more new lesions. 
Stable Disease (SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum LD since the treatment started. 
 
 
Evaluation of Non-Target Lesions 
Complete Response (CR) 
Disappearance of all non-target lesions and normalization of tumor marker level.  All lymph 
nodes must be non-pathological in size (< 10 mm short axis). 
Incomplete Response/Stable Disease (SD) 
Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level 
above the normal limits. 
Progressive Disease (PD) 
Appearance of one or more new lesions and/or unequivocal progression of existing non-target 
lesions. 
 
 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started). The patient's best response assignment will depend on the 
achievement of both measurement and confirmation criteria. 
Table 5 Response Criteria 
 
Target 
Lesions 
Non-Target 
Lesions 
New 
Lesions 
Overall 
Response 
Best Response for this 
Category Also Requires 
CR 
CR 
No 
CR 
≥4 weeks confirmation 
CR 
PR 
Non-CR/  Non- 
PD 
Non-PD 
No 
No 
PR 
PR 
 
≥4 weeks confirmation 
SD 
Non-PD 
No 
SD 
documented at least once ≥4 
weeks from baseline 
PD 
Any 
Any 
Any 
PD * 
Any 
Yes or No 
Yes or No 
Yes 
PD 
PD 
PD 
 
No prior SD, PR, or CR 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 57
 
 
* In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease 
progression 
 
7.1.2 IMMUNE RELATED RESPONSE CRITERIA (IRRC) 
Definitions of measurable and non-measurable disease 
Measurable disease 
Neoplastic masses that can be precisely measured in 2 in-plane perpendicular diameters. Both 
its longest diameter and its longest perpendicular must be greater than or equal to 10 mm or 2 
times the axial slice thickness. Lymph nodes must have a short-axis line-length of ≥ 15 mm. 
Malignant lymph nodes must be measurable in 2 perpendicular diameters. Both its longest 
diameter and its longest perpendicular must be greater than or equal to 15 mm or 2 times the 
axial slice thickness. The quantitative endpoint will be defined as the product of the longest 
diameter with its longest perpendicular. 
 
 
Non-measurable disease 
Non-measurable lesions are those that are not suitable for quantitative assessment over time. 
These include: 
1. Neoplastic masses that are too small to measure, because their longest uninterrupted 
diameter or longest perpendicular are less than 10 mm or two times the axial slice thickness. 
2. Neoplastic masses whose boundaries cannot be distinguished. This includes masses which 
cannot be demarcated from surrounding tissue because of inadequate contrast, masses with 
overly complex morphology, or those with highly heterogeneous tissue composition. 
3. Other types of lesions that are confidently felt to represent neoplastic tissue, but difficult to 
quantify in a reproducible manner. These include bone metastases, leptomeningeal metastases, 
malignant ascites, pleural/pericardial effusions, inflammatory breast disease, lymphangitis 
cutis/pulmonis, cystic lesions, ill defined abdominal masses, etc. 
 
 
For irRC, only target lesions selected at baseline and measurable new lesions are taken into account. 
At the baseline tumor assessment, the sum of the products of the two largest perpendicular diameters 
(SPD) of all index lesions (five lesions per organ, up to 10 visceral lesions and five cutaneous index 
lesions) is calculated. 
At each subsequent tumor assessment, the SPD of the index lesions and of new, measurable lesions (≥5 
X 5 mm; up to 5 new lesions per organ: 5 new cutaneous lesions and 10 visceral lesions) are added 
together to provide the total time-point tumor burden. 
 
 
Overall response using irRC: 
Complete Response (irCR) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 58
 
 
Complete disappearance of all tumor lesions (whether measureable or not, and no new 
lesions). CR must be confirmed by repeated, consecutive assessments made no less than 4 
weeks from the date first documented. 
Partial Response (irPR) 
Decrease in SPD of 50% or greater by a consecutive assessment at least 4 weeks after first 
documentation. 
Stable Disease (irSD) 
Failure to meet criteria for irCR or irPR, in absence of irPD. 
Progressive Disease (irPD) 
At least 25% increase in SPD relative to nadir (minimum recorded tumor burden) 
Confirmation by a repeat, consecutive assessment no less than 4 weeks from the data first 
documented. 
Please note other key differences between irRC and the original WHO criteria: New measurable lesions 
will be incorporated into the SPDNew non measurable lesions do not define progression but preclude 
irCR 
 
 
Non-index lesions contribute to defining irCR (complete disappearance required). IrRC for the current 
protocol is adopted from Wolchok et al (2009). 
 
7.2 
EVALUATION OF SAFETY 
Analyses will be performed for all patients having received at least one dose of study drug. The study 
will use the CTCAE v4.0 for reporting of adverse events. Safety will be assessed during the study by 
documentation of adverse events (AEs), clinical laboratory tests, physical examination, vital sign 
measurements, and Eastern Cooperative Oncology Group (ECOG) performance status. 
For multicenter studies, the Principal Investigator at the UCSF Coordinating Center will hold the role of 
Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its 
safety and progress at all participating sites. 
 
 
7.2.1 EVALUATING ADVERSE EVENTS 
An investigator who is a qualified physician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which changes 
CTCAE grade over the course of a given episode will have each change of grade recorded on the 
adverse event case report forms/worksheets. 
All adverse events regardless of CTCAE grade must also be evaluated for seriousness. 
 
 
Definitions of Adverse Events 
7.2.1.1 Adverse Event 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 59
 
 
An adverse event (also known as an adverse experience) is defined as any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered drug related.  More 
specifically, an adverse event (can be any unfavorable and unintended sign (e.g., an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a drug, without any 
judgment about causality. An adverse event can arise from any use of the drug (e.g., off-label use, use in 
combination with another drug) and from any route of administration, formulation, or dose, including 
an overdose. Any untoward medical occurrence prior to dosing at C1D1 will be recorded as         
Medical History. 
7.2.1.2 Adverse reaction 
An adverse reaction is defined as any adverse event caused by the use of a drug.  Adverse reactions are 
a subset of all suspected adverse reactions for which there is reason to conclude that the drug caused 
the event. 
7.2.1.3 Suspected 
A suspected adverse reaction is defined as any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safety reporting, 
“reasonable possibility”  indicates  that there is  evidence to suggest a causal relationship between 
the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty 
about causality than an adverse reaction. 
7.2.1.4 Unexpected 
An adverse event or suspected adverse reaction is considered unexpected if it is not listed in the 
investigator brochure or package insert(s), or is not listed at the specificity or severity that has been 
observed, or, if an investigator brochure is not required or available, is not consistent with the risk 
information described in the general investigational plan or elsewhere in the current application. 
“Unexpected,” as used in this definition, also refers to adverse events or suspected adverse reactions 
that are mentioned in the investigator brochure as occurring with a class of drugs or as  anticipated 
from the pharmacological properties  of  the drug, but are not specifically mentioned as occurring 
with the particular drug under investigation. 
Adverse events  that would be anticipated to occur as  part of the  disease process  are considered 
unexpected for the purposes of reporting because they would not be listed in the investigator  
brochure.   For example, a certain number of non-acute deaths in a cancer trial would be anticipated as 
an outcome of the underlying disease, but such deaths would generally not be listed as a suspected 
adverse reaction in the investigator brochure. 
 
 
Some adverse events are listed in the Investigator Brochure as occurring with the same class of drugs, 
or as anticipated from the pharmacological properties of the drug, even though they have not been 
observed with the drug under investigation.  Such events would be considered unexpected until they 
have been observed with the drug under investigation. For example, although angioedema is 
anticipated to occur in some patients exposed to drugs in the ACE inhibitor class and angioedema 
would be described in the investigator brochure as a class effect, the first case of angioedema observed 
with the drug under investigation should be considered unexpected for reporting purposes. 
7.2.1.5 Serious 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 60
 
 
An adverse event or suspected adverse reaction is considered serious if, in the view of either the 
Investigator or Sponsor-Principal Investigator, it results in any of the following outcomes: 
• Death 
• Life-threatening adverse event 
• Inpatient hospitalization or prolongation of existing hospitalization 
• 
A persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life function 
• 
Congenital anomaly/birth defect 
• 
Note: In addition to the above criteria, adverse events meeting either of the below criteria, although 
not serious per ICH definition, are reportable to the Merck in the same timeframe as SAEs to meet certain 
local requirements. Therefore, these events are considered serious by Merck for collection purposes. 
● 
Is a new cancer (that is not a condition of the study); 
● 
Is associated with an overdose. 
Important medical events that may not result in death, are life-threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
7.2.1.6 Life-threatening 
An adverse event or suspected adverse reaction is considered life-threatening if, in the view of either 
the Investigator or Sponsor-Principal Investigator, its occurrence places the patient or subject at 
immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it 
occurred in a more severe form, might have caused death. 
 
7.2.2 EVENTS OF CLINICAL INTEREST 
Events of clinical interest for this trial include: 
1. an overdose of investigational product, as defined in Section 7.6, that is not associated with clinical 
symptoms or abnormal laboratory results. 
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an 
elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal and, at the 
same time, an alkaline phosphatase lab value that is less than 2X the upper limit of normal, as 
determined by way of protocol-specified laboratory testing or unscheduled laboratory testing.* 
 
 
*Note:   These criteria are based upon available regulatory guidance documents. The purpose of 
the criteria is to specify a threshold of abnormal hepatic tests that may require an additional 
evaluation for an underlying etiology. 
 
 
7.3 RECORDING OF AN ADVERSE EVENT 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 61
 
 
All adverse events, regardless of grade, will be entered into the Medidata RAVE EDC system. For the 
primary UCSF clinical site, all grade 3 and above adverse events will be entered into OnCore®, whether 
or not the event is believed to be associated with use of the study drug. Data about these events and 
their severity will be recorded using the NCI CTCAE v4.0.   Note: satellite sites will not be required to 
enter the information into OnCore®. 
 
 
The Investigator will assign attribution of the possible association of the event with use of the 
investigational drug, and this information will be entered into Medidata RAVE (and OnCore® when 
appropriate) using the classification system listed below: 
 
 
Relationship 
Attribution 
Description 
 
Unrelated 
The  AE   is 
intervention 
clearly NOT related to the 
 
 
Unrelated to investigational 
drug/intervention 
 
Unlikely 
The 
AE 
is 
doubtfully 
intervention 
related 
to the 
Possible 
The AE may be related to the intervention 
Related   to investigational 
drug/intervention 
Definite 
The AE is clearly related to the intervention 
 
Signs or symptoms reported as adverse events will be graded and recorded by the Investigator 
according to the CTCAE. When specific adverse events are not listed in the CTCAE they will be graded 
by the Investigator as none, mild, moderate or severe according to the following grades and definitions: 
 
Grade 0 
No AE (or within normal limits) 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade 2 
Moderate; minimal, local, or  noninvasive intervention (e.g., packing, cautery) 
indicated; limiting age-appropriate instrumental activities of daily living (ADL) 
Grade 3: 
Severe or medically significant but not immediately life-threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self-care ADL 
Grade 4: 
Life-threatening consequences; urgent intervention indicated 
Grade 5: 
Death related to AE 
 
7.4 FOLLOW-UP OF ADVERSE EVENTS 
All adverse events  will be followed  with  appropriate medical management until resolved. 
Patients removed from study for unacceptable adverse events will be followed until resolution or 
stabilization of the adverse event. For selected adverse events for which administration of the 
investigational drug was stopped, a re-challenge of the subject with the investigational drug may be 
conducted if considered both safe and ethical by the Investigator. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 62
 
 
7.5 ADVERSE EVENTS MONITORING 
All adverse events, whether or not unexpected, and whether or not considered to be associated with 
the use of the study drug(s), will be entered into Medidata Rave®, or a paper case report form, as noted 
above. 
The Sponsor-Principal Investigator (or designee) will assess all adverse events and determine 
reportability requirements to the UCSF Data and Safety Monitoring Committee (DSMC) and UCSF’s 
Institutional Review Board; and, when the study is conducted under an Investigational New Drug 
Application (IND), to the Food and Drug Administration (FDA) if it meets the FDA reporting criteria. 
 
 
All adverse events entered into Medidata Rave® will be reviewed by OncoSec Medical Inc. and 
monitoring reports will be reviewed by the Sponsor-Principal Investigator and/or UCSF’s DSMC on an 
ongoing basis. 
All grade(s) 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the Site 
Committee meetings. The Site Committee will review and discuss the selected toxicity, the toxicity 
grade, and the attribution of relationship of the adverse event to the administration of the study 
drug(s). 
In addition, all suspected adverse reactions considered “serious” entered into OnCore®, will be 
reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and 
discussed at DSMC meetings, which take place approximately every six weeks. 
For a detailed description of the Data and Safety Monitoring Plan for a Multicenter Phase 2 or 3 
Institutional Study at the Helen Diller Comprehensive Cancer Center please refer to Appendix 2 
Multicenter Institutional Studies. 
 
7.6 EXPEDITED REPORTING 
Reporting to the Data and Safety Monitoring Committee 
If a death occurs during the treatment phase of the study or within 30 days after the last 
administration of the study drug(s) and it is determined to be related either to the study 
drug(s) or to a study procedure, the Sponsor-Principal Investigator or his/her designee must 
notify the DSMC Chair (or qualified alternate) within 1 business day of knowledge of the event. 
The contact may be by phone or e-mail. 
Reporting to UCSF Institutional Review Board 
The Sponsor-Principal Investigator must report events meeting the UCSF IRB definition of 
“Unanticipated Problem” (UP) within 5 business days of his/her awareness of the event. 
Expedited Reporting to the Food and Drug Administration 
If the study is being conducted under an IND, the Sponsor-Principal Investigator is responsible 
for determining whether or not the suspected adverse reaction meets the criteria for expedited 
reporting in accordance with Federal Regulations (21 CFR §312.32). 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 63
 
 
The Sponsor-Principal Investigator must report in an IND safety report any suspected adverse 
reaction that is both serious and unexpected. The Sponsor-Principal Investigator needs to 
ensure that the event meets all three definitions: 
o 
Suspected adverse reaction 
o 
Unexpected 
o 
Serious 
 
If the adverse event does not meet all three of the definitions, it should not be submitted as an 
expedited IND safety report. 
The timeline for submitting an IND safety report to FDA is no later than 15 calendar days after 
the Sponsor-Principal Investigator determines that the suspected adverse reaction qualifies for 
reporting (21 CFR 312.32(c)(1)). 
Any unexpected fatal or life-threatening suspected adverse reaction will be reported to FDA no 
later than 7 calendar days after the Sponsor-Principal Investigator’s initial receipt of the 
information (21 CFR 312.32(c)(2)). 
Any relevant additional information that pertains to a previously submitted IND safety report 
will be submitted to FDA as a Follow-up IND Safety Report without delay, as soon as 
the information is available (21 CFR 312.32(d)(2)). 
Expedited Reporting to Merck and OncoSec Medical Inc. Reporting of Overdose 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 
mg or greater (≥5 times the indicated dose). No specific information is available on the 
treatment of overdose of pembrolizumab. In the event of overdose, the current infusion of 
pembrolizumab should be discontinued and the subject should be observed closely for signs of 
toxicity. Appropriate supportive treatment should be provided if clinically indicated. 
If an adverse event(s) is associated with (“results from”) the overdose of an investigational 
product, the adverse event(s) is reported as a serious adverse event, even if no other 
seriousness criteria are met and should be reported to the Sponsor-Principal Investigator (or 
designee) within 24 hours. 
If a dose meeting the protocol definition of overdose is taken without any associated clinical 
symptoms or abnormal laboratory results, the overdose is reported as a non-serious Event of 
Clinical Interest (ECI), using the terminology “accidental or intentional overdose without 
adverse effect.” 
All reports of overdose with and without an adverse event must be reported within 24 hours to 
the Sponsor-Principal Investigator (or designee). It is then the responsibility of UCSF as the 
Sponsor to complete reporting to Merck Global Safety (Attn: Worldwide Product Safety; FAX 
215 993-1220) and to OncoSec Medical Inc (Attn: Medical Monitor; Email: 
safety@oncosec.com). 
Reporting of Pregnancy and Lactation 
Although pregnancy and lactation are not considered adverse events, it is the responsibility of 
Investigators or their designees to report any pregnancy or lactation in a subject 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 64
 
 
(spontaneously reported to them) that occurs during the trial or within 120 days of completing 
the trial completing the trial, or 30 days following cessation of treatment if the subject initiates 
new anticancer therapy, whichever is earlier. All subjects and female partners of male subjects 
who become pregnant must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported. 
Such events must be reported within 24 hours to the Sponsor-Principal Investigator (or 
designee). It is then the responsibility of UCSF as the Sponsor to complete reporting to Merck 
Global Safety (Attn: Worldwide Product Safety; Fax: 215-993-1220) and to OncoSec Medical 
Inc (Attn: Medical Monitor; Email: safety@oncosec.com). 
Immediate Reporting of Adverse Events 
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause other than progression of the cancer under study that occurs 
to any subject must be reported within 24 hours to the Sponsor-Principal Investigator and 
within 2 working days to Merck Global Safety and to OncoSec Medical Inc if it causes the 
subject to be excluded from the trial, or is the result of a protocol-specified intervention, 
including but not limited to washout or discontinuation of usual therapy, diet, placebo 
treatment or a procedure. 
For the time period beginning at treatment allocation/randomization through 90 days 
following cessation of treatment, or 30 days following cessation of treatment if the subject 
initiates new anti-cancer therapy, whichever is earlier, any serious adverse event, or follow up 
to a serious adverse event, including death due to any cause other than progression of the 
cancer under study, whether or not related to any of the investigational products, must be 
reported within 24 hours to the Sponsor-Principal Investigator (or designee). It is then the 
responsibility of UCSF as the Sponsor to complete reporting to Merck Global Safety and 
OncoSec Medical Inc.. 
Additionally, any serious adverse event, considered by an Investigator who is a qualified 
physician to be related to the investigational products that is brought to the attention of the 
Investigator at any time following consent through the end of the specified safety follow-up 
period specified in the paragraph above, or at any time outside of the time period specified in 
the previous paragraph also must be reported immediately to the Sponsor-Principal 
Investigator (or designee). It is then the responsibility of UCSF as the Sponsor to complete 
reporting to Merck Global Safety and OncoSec Medical Inc. 
SAE reports and any other relevant safety information are to be forwarded to the 
Sponsor- Principal Investigator (or designee). It is then the responsibility of UCSF as the 
Sponsor to complete reporting to Merck (Attn: Worldwide Product Safety; Fax: 215-993- 
1220) and OncoSec Medical Inc (Attn: Medical Monitor; Email: safety@oncosec.com). 
A copy of all 15 Day Reports and Annual Progress Reports submitted as required by FDA or 
other local regulators will be submitted to Merck & Co., Inc. (Attn: Worldwide Product Safety; 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 65
 
 
Fax: 215-993-1220) and OncoSec Medical Inc. (Attn: Medical Monitor; Email: 
safety@oncosec.com) at the time of submission to FDA. 
All subjects with serious adverse events must be followed up for outcome. A copy of these 
reports must also be submitted to OncoSec Medical Inc (Attn: Medical Monitor; Email: 
safety@oncosec.com). 
Events of Clinical Interest 
 
Selected non-serious and serious adverse events are also known as Events of Clinical Interest 
(ECI) and must be reported within 24 hours to the Sponsor-Principal Investigator (or 
designee). It is then the responsibility of UCSF as the Sponsor to complete reporting within 2 
working days to Merck Global Safety (Attn: Worldwide Product Safety; FAX 215 993-1220) and 
to OncoSec Medical Inc (Attn: Medical Monitor; Email: mlesafety@oncosec.com). 
 
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject 
must be reported within 24 hours to the Sponsor and within 2 working days to Merck 
Global Safety if it causes the subject to be excluded from the trial, or is the result of a 
protocol-specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure. 
For the time period beginning at treatment allocation/randomization through 90 days 
following cessation of treatment, or 30 days following cessation of treatment if the 
subject initiates new anticancer therapy, whichever is earlier, any ECI, or follow up to 
an ECI, whether or not related to Merck product, must be reported within 24 hours to 
the Sponsor-Principal Investigator or his/her designee and within 24 hours to Merck 
Global Safety. It is then the responsibility of UCSF as the Sponsor to complete 
reporting to Merck Global Safety and to OncoSec Medical Inc. 
 
 
See Section 7.2.2 for definitions of events of clinical interest. 
 
Protocol-Specific Exceptions to Serious Adverse Event Reporting 
 
Efficacy endpoints as outlined in this section will not be reported to Merck as described in 
Immediate Reporting of Adverse Events, unless there is evidence suggesting a causal 
relationship between the drug and the event. Any such event will be submitted to the Sponsor- 
Principal Investigator within 24 hours and to Merck Global Safety and and to OncoSec Medical 
Inc. within 2 working days either by electronic or paper media. 
Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study. 
 
The Sponsor-Principal Investigator will monitor unblinded aggregated efficacy endpoint 
events and safety data to ensure the safety of the subjects in the trial. Any suspected endpoint 
which upon review is not progression of the cancer under study will be forwarded to Merck 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 66
 
 
Global Safety and to OncoSec Medical Inc. as a SAE within 2 working days of determination that 
the event is not progression of the cancer under study. 
 
Hospitalization related to convenience (e.g.transportation issues etc.) will not be considered a 
SAE. 
8 STATISTICAL CONSIDERATIONS AND EVALUATION OF RESULTS 
8.1 STUDY ENDPOINTS 
8.1.1 PRIMARY ENDPOINT 
Best overall objective response rate (ORR), CR + PR, within 24 weeks of first treatment with 
pIL-12 electroporation and pembrolizumab will be determined by RECIST v1.1 and compared 
against historical response rates for pembrolizumab as a monotherapy in a similar population. 
8.1.2 SECONDARY ENDPOINTS 
Safety and tolerability is defined by assessment of adverse events. These will be assessed using 
the NCI CTCAE. 
Duration of response (DOR) for those experiencing CR or PR is the number of days from the 
initial documentation of an objective response to the most current evaluation of that response 
(censored duration) or to documentation of progression. 
Twenty-four week landmark progression free survival (PFS at 24 weeks) is defined as the % of 
patients who have either progressed or not progressed at 24 weeks. 
Progression free  survival (PFS) is defined as the duration between the date of  treatment 
initiation to the first date of either disease progression or death. 
Overall survival (OS) is defined as the duration between the date of treatment initiation to the 
date of death, regardless of the cause of death. 
Best overall objective response rate (ORR), CR + PR, determined by immune-related Response 
Criteria (irRC). 
8.1.3 EXPLORATORY ENDPOINTS 
Co-primary candidate biomarkers to be investigated in this study include PD-L1 expression 
levels assessed by IHC and TIL profile assessed by CD8 T cell density in tumor tissue. Changes 
in PD-L1 expression will be assessed pre- and post-treatment using at least one of the 
following IHC-based assays: (1) the Merck developed PD-L1 IHC assay (clone 22C3) with a 
stringent cut-off negative of <1% in tumor or stromal cells of the tumor environment or (2) an 
assay developed by Tumeh/UCLA [42] with a low TIL cut-off of <600 CD8 cells/mm2. If tumor 
samples demonstrate that the combination therapy converts tumors from low TIL to high TIL 
but without a corresponding increase in ORR, then the hypothesis that enhancing TILs will 
increase pembrolizumab efficacy can be rejected. Changes in other biomarkers and immune 
responses in tissue and blood will be assessed for association with clinical outcome (efficacy 
endpoints). 
 
8.1.4 STUDY DESIGN 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 67
 
 
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 
EP in combination with pembrolizumab in patients with melanoma. Patients will be 
evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that 
quantifies intratumoral PD-1hiCD8+CTLA4+ “exhausted” lymphocytes in the tumor. Part B 
will enroll patients who have or are failing pembrolizumab at least 12 weeks after starting 
PD-1 antibody alone or in combination, or, who have been selected using a flow cytometric 
assay that quantifies intratumoral PD-1hiCD8+CTLA4+ “exhausted” lymphocytes in the 
tumor. 
 
 
8.1.5 SAMPLE SIZE AND POWER ESTIMATE 
Best ORR by RECISTv1.1 within 24 weeks is the primary efficacy endpoint for this study. Given 
that this preliminary study is a single-arm combination study with a historical comparator, 
the sample size depends upon the presumed “baseline pembrolizumab ORR” in the biomarker 
selected population. The assumnption was made that the false negative rate of the assay in 
this projected patient population defines the H0 for the study. Based on analysis of UCSF 
patients treated with pembrolizumab as a monotherapy, we estimate the false negative rate 
of the flow cytometric assay as 12.5%. Therefore, a 42 patient study will meet the following 
statistical parameters: H0 = 12.5%; Halt = 30%; alpha of 0.025 (actual; one-sided test); power 
= 85%. 
 
8.1.6 REPLACEMENT POLICY 
Patients who discontinue from the study for reasons unrelated to the study will be replaced as 
required for the study to meet its objectives. The decision to remove a subject/patient and to 
replace dropouts will documented and made jointly by the Sponsor-Principal Investigator 
and study statistician. 
 
8.1.7 ACCRUAL ESTIMATES 
This study plans to complete enrollment 18 months after opening to accrual. It is estimated that 
roughly half of the patient population will have PD-L1-negative melanoma meeting the 
eligibility criteria for enrollment. Given an estimation of 100 patients that would be candidates 
for an anti-PD-1 therapy seen per year at the primary clinical site alone, completion of 
enrollment across multiple sites within 18 months can be attained. Recruitment of other clinical 
sites for participation in this trial further supports achievable accrual of 42 evaluable patients 
within 18 months. 
 
 
8.2 ANALYSES PLANS 
8.2.1 ANALYSIS POPULATION 
8.2.1.1 Primary Analysis (or Analysis of Primary Endpoints) 
 
THE PRIMARY EFFICACY ANALYSES WILL BE BASED ON THE FULL ANALYSIS SET (FAS) 
POPULATION. PATIENTS WITH MEASURABLE DISEASE AT BASELINE, WHICH IS DEFINED 
SEPARATELY UNDER INVESTIGATOR EVALUATION, WHO RECEIVED AT LEAST ONE DOSE OF 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 68
 
 
INTRATUMORAL PIL-12-EP AND PEMBROLIZUMAB STUDY TREATMENT WILL BE INCLUDED IN 
THE FAS POPULATIONSAFETY ANALYSIS SETS 
Safety analysis set: The safety analysis set comprises all enrolled patients who received any amount of 
study drug. 
 
 
8.2.1.2 Secondary Analysis (or Analysis of Secondary Endpoints) 
Analyses of PFS and OS are based on the All Patients as Treated (APaT) population. The APaT 
population consists of all patients who received at least 1 dose of intratumoral pIL-12-EP and 
pembrolizumab study treatment. PFS and OS will also be analyzed based on the FAS. Analysis of DOR 
will be based on patients that experience CR or PR at the time of disease evaluations while on study. 
Analyses to satisfy exploratory endpoints will be based on the All Patients as Treated (APaT) 
population, consisting of all patients who received at least 1 dose of study treatment. 
Future Biomedical Research: 
Future biomedical research on blood and leftover tumor biopsy specimens will be performed on 
collected samples during this clinical trial. This research may include genetic analyses (DNA), gene 
expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or the measurement of 
other analytes. This research is for biomarker testing to address emergent questions not described 
elsewhere in the protocol (as part of the main biomarker correlative objectives). The objective is to 
explore and identify biomarkers that inform scientific understanding of this therapeutic treatment. 
The specimens will be stored to provide a resource for studies conducted by trial partners focused on 
the study of biomarkers responsible for the mechanism of action and to answer emerging questions 
surrounding pathway involvement or other aspects of disease. It is well recognized that information 
obtained from additional studies conducted on clinical specimens offers  greater  understanding of 
patient response to therapy and  the potential for development of  novel treatments or enhanced 
targeted to populations with the greatest need. 
 
8.3 EVALUATION OF SAFETY 
Analyses will be performed for all patients having received at least one dose of study drug. The study 
will use the NCI CTCAE v4.0 and guidance provided in Section 7.2. 
 
8.4 INTERIM ANALYSIS AND STOPPING RULES 
An interim safety analysis will be performed after 15 patients have been treated on study. If 5 of these 
15 patients have had treatment-related serious adverse events as defined in the protocol, the accrual 
will be stopped and the study will be terminated. 
 
 
8.5 CLINICAL CRITERIA FOR EARLY TRIAL TERMINATION 
Early trial termination will be the result of the criteria specified below: 
1. Quality or quantity of data recording is inaccurate or incomplete 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 69
 
 
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential health 
hazard to subjects 
4. Plans to modify or discontinue the development of the study drug 
5. Study meets stopping criteria per interim analysis results 
6. Sponsor terminates the trial 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 70
 
 
9 STUDY MANAGEMENT 
9.1 PRE-STUDY DOCUMENTATION 
This study will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki as stated in 21 CFR §312.120(c)(4); consistent with GCP and all applicable 
regulatory requirements. 
Before initiating this trial, the Investigator will have written and dated approval from the Institutional 
Review Board for the protocol, written informed consent form, subject recruitment materials, and any 
other written information to be provided to subjects before any protocol related procedures are 
performed on any subjects. 
The clinical investigation will not begin until either FDA has determined that the study under the 
Investigational Drug Application (IND) is  allowed to proceed or the Sponsor-Principal 
Investigator has received a letter from FDA stating that the study is exempt from IND requirements. 
The Investigator must comply with the applicable regulations in Title 21 of the Code of Federal 
Regulations (21 CFR §50, §54, and §312), GCP/ICH guidelines, and all applicable regulatory 
requirements.  The IRB must comply with the regulations in 21 CFR §56 and applicable regulatory 
requirements. 
 
9.2 INSTITUTIONAL REVIEW BOARD APPROVAL 
The protocol, the proposed informed consent form, and all forms of participant information related to 
the study (e.g. advertisements used to recruit participants) will be reviewed and approved by the UCSF 
Institutional Review Board.  Prior to obtaining IRB approval, the protocol must be approved by the 
Helen Diller Family Comprehensive Cancer Center Site Committee and by the Protocol Review 
Committee (PRC). The initial protocol and all protocol amendments must be approved by the IRB prior 
to implementation. 
 
9.3 INFORMED CONSENT 
All participants must be provided a consent form describing the study with sufficient information for 
each participant to make an informed decision regarding their participation.  Participants must sign 
the CHR-approved informed consent form prior to participation in any study specific procedure. The 
participant must receive a copy of the signed and dated consent document. The original signed copy of 
the consent document must be retained in the medical record or research file. 
Consent must be documented by the subject’s dated signature or by the subject’s legally acceptable 
representative’s dated signature on a consent form along with the dated signature of the person 
conducting the consent discussion. 
A copy of the signed and dated consent form should be given to the subject before participation in the 
trial. 
The initial informed consent form, any subsequent revised written informed consent form and any 
written information provided to the subject must receive the IRB/ERC’s approval/favorable opinion in 
advance of use.  The subject or his/her legally acceptable representative should be informed in a 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 71
 
 
timely manner if new information becomes available that may be relevant to the subject’s willingness 
to continue participation in the trial. The communication of this information will be provided and 
documented via a revised consent form or addendum to the original consent form that captures the 
subject’s dated signature or by the subject’s legally acceptable representative’s dated signature. 
Specifics about a trial and the trial population will be added to the consent form template at the 
protocol level. 
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and 
Sponsor requirements. 
 
 
9.4 CHANGES IN THE PROTOCOL 
Once the protocol has been approved by the UCSF IRB, any changes to the protocol must be 
documented in the form of an amendment. The amendment must be signed by the Sponsor- Principal 
Investigator and approved by PRC and the IRB prior to implementation. 
If it becomes necessary to alter the protocol to eliminate an immediate hazard to patients, an 
amendment may be implemented prior to IRB approval. In this circumstance, however, the Sponsor- 
Principal Investigator must then notify the IRB in writing within five (5) working days after 
implementation.  The Study Chair and the UCSF study team will be responsible for updating any 
participating sites. 
 
 
9.5 HANDLING AND DOCUMENTATION OF CLINICAL SUPPLIES 
The UCSF Principal Investigator and Investigators at each participating site will maintain complete 
records showing the receipt, dispensation, return, or other disposition of all investigational drugs and 
the EP devices. The date, quantity and batch or code number of the drug, and the identification of 
patients to whom study drug has been dispensed by patient number and initials will be included. The 
Investigator will maintain written records of any disposition of the study drug. 
The Investigator shall not make the investigational drug available to any individuals other than to 
qualified study patients. Furthermore, the Investigator will not allow the investigational drug to be 
used in any manner other than that specified in this protocol. 
 
 
9.6 CASE REPORT FORMS (CRFS) 
The Investigator and/or his/her designee will prepare and maintain adequate and accurate 
participant case histories with observations and data pertinent to the study. Study specific electronic 
Case Report Forms (eCRFs) will document safety and treatment outcomes for safety monitoring and 
data analysis. All study data will be entered onto paper CRFs or into Medidata Rave® via data entry 
screens for eCRFs in accordance with the CTMS study calendar, using single data entry with a secure 
access account.  Data may be captured on paper CRFs for patients who continue treatment beyond 24 
months. The Clinical Research Coordinator (CRC) will complete the CRFs as soon as possible upon 
completion of the study visit; the Investigator will review and approve the completed eCRFs. 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 72
 
 
The information collected on eCRFs shall be identical to that appearing in original source documents. 
Source documents will be found in the patient’s medical records maintained by clinical site.  All source 
documentation should be kept in separate research folders for each patient. 
In accordance with federal regulations, the Investigator is responsible for the accuracy and 
authenticity of all clinical and laboratory data entered onto eCRFs.  The Investigator will approve all 
completed eCRFs to attest that the information contained on the eCRFs is true and accurate. 
All source documentation and CTMS data will be available for review/monitoring by the UCSF DSMC 
and regulatory agencies. OncoSec will be the primary entity responsible for monitoring the data. 
The Investigator will be responsible for ensuring the accurate capture of study data.  At study 
completion, when the eCRFs have been declared to be complete and accurate, the database will be 
locked.  Any changes to the data entered into the eCRFs after that time can only be made by joint 
written agreement among the Study Chair, the Trial Statistician, and the Protocol Project Manager. 
Each  participating site will complete study specific  CRFs for safety monitoring and data analysis. 
Each site will enter the study data into Medidata Rave® via standardized CRFs using single data entry 
with a secure access account. The participating site’s Clinical Research Coordinator (CRC) will 
complete the CRFs (including any deviations) within 10 business days of the visit; the Investigator will 
review and approve the completed CRFs. Study data from the participating site will be reported and 
reviewed in aggregate with data from patients enrolled at the coordinating center, UCSF. All source 
documentation and CTMS data will be available for review/monitoring as needed. 
 
 
9.7 OVERSIGHT AND MONITORING PLAN 
OncoSec Medical Inc. will be the monitoring entity for this study. OncoSec will be monitoring the 
patient and regulatory data for this trial and providing the UCSF DSMC with the monitoring reports for 
review. The UCSF DSMC will provide monitoring oversight. The DSMC will routinely review all adverse 
events and suspected adverse reactions considered “serious”. The DSMC will audit study- related 
activities to ensure that the study is conducted in accordance with the protocol, local standard 
operating procedures, FDA regulations, and Good Clinical Practice (GCP).  Significant results of the 
DSMC audit will be communicated to the IRB and the appropriate regulatory authorities at the time of 
continuing review, or in an expedited fashion, as applicable.  See Appendix 2 Data and Safety 
Monitoring Plan for additional information. 
 
 
9.8 MULTICENTER COMMUNICATION 
The UCSF Coordinating Center provides administration, data management, and organizational support 
for the participating sites in the conduct of a multicenter clinical trial.  The UCSF Coordinating Center 
or designee (OncoSec Medical Inc.) for Phase II studies will also coordinate, at minimum, monthly 
conference calls with the participating sites or more frequently as needed to discuss risk assessment. 
The following issues will be discussed as appropriate: 
• 
Enrollment information 
• 
Adverse events (i.e., new adverse events and updates on unresolved adverse events and new 
safety information) 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 73
 
 
• 
Protocol violations 
• 
Other issues affecting the conduct of the study 
 
 
9.9 RECORD KEEPING AND RECORD RETENTION 
The Investigator is  required to maintain adequate records  of  the disposition of the  drug, 
including dates, quantity, and use by subjects, as well as written records of the disposition of the drug 
when the study ends. 
The Investigator is required to prepare and maintain adequate and accurate case histories that record 
all observations and other data pertinent to the investigation on each individual administered the 
investigational drug or employed as  a control in the investigation. Case histories include the case 
report forms and supporting data including, for example, signed and dated consent forms  and 
medical records including, for example, progress notes  of  the physician, the individual's hospital 
chart(s), and the nurses' notes. The case history for each individual shall document that informed 
consent was obtained prior to participation in the study. 
Study documentation includes all eCRFs, data correction forms or queries, source documents, Sponsor- 
Principal Investigator correspondence, monitoring logs/letters, and regulatory documents (e.g., 
protocol and amendments, IRB correspondence and approval, signed patient consent forms). 
Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study. 
In accordance with FDA regulations, the Investigator shall retain records for a period of 2 years 
following the date a marketing application is approved for the drug for the indication for which it is 
being investigated; or, if no application is to be filed or if the application is not approved for such 
indication, until 2 years after the investigation is discontinued and FDA is notified. 
 
 
9.10 COORDINATING CENTER DOCUMENTATION OF DISTRIBUTION 
It is the responsibility of the Study Chair to maintain adequate files documenting the distribution of 
study documents as well as their receipt (when possible). The HDFCCC recommends that the Study 
Chair maintain a correspondence file and log for each segment of distribution (e.g., FDA, drug 
manufacturer, participating sites, etc.). 
Correspondence file: should contain copies (paper or electronic) of all protocol versions, cover letters, 
amendment outlines (summary of changes), etc., along with distribution documentation and (when 
available) documentation of receipt. 
Correspondence log: should be a brief list of all documents distributed including the date sent, 
recipient(s), and (if available) a tracking number and date received. 
At a minimum, the Study Chair must keep documentation of when and to whom the protocol, its 
updates and safety information are distributed. 
 
 
9.11 STUDY PERSONNEL TRAINING PLAN 


Version date: 10-12-2017
Protocol CC#:15852
IT-pIL12-EP and anti-PD-1
Page 74
 
 
Study personnel from all participating sub-sites (not including UCSF) must receive training from UCSF 
or designee (OncoSec Medical Inc.) before the site may be activated to enroll patients. This training 
will include, but is not limited to, protocol and GCP overview, AE reporting, proper administration of 
study treatments, and review of study objectives and study procedures. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 75
 
 
 
10 PROTECTION OF HUMAN SUBJECTS 
10.1 PROTECTION FROM UNNECESSARY HARM 
Each clinical site is responsible for protecting all subjects involved in human experimentation. This is 
accomplished through the CHR mechanism and the process of informed consent. The CHR reviews all 
proposed studies involving human experimentation and ensures that the subject’s rights and welfare 
are protected and that the potential benefits and/or the importance of the knowledge to be gained 
outweigh the risks to the individual. The CHR also reviews the informed consent document associated 
with each study in order to ensure that the consent document accurately and clearly communicates 
the nature of the research to be done and its associated risks and benefits. 
 
 
10.2 PROTECTION OF PRIVACY 
Patients will be informed of the extent to which their confidential health information generated from 
this study may be used for research purposes. Following this discussion, they will be asked to sign the 
HIPAA form and informed consent documents. The original signed document will become part of the 
patient’s medical records, and each patient will receive a copy of the signed document. The use and 
disclosure of  protected health information will be limited  to the individuals described in the 
informed consent document. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 76
 
 
 
REFERENCES 
1. Howlader, N., et al. (2009). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 
Populations). Bethesda, MD, National Cancer Institute. 
2. American 
Cancer 
Society. 
Cancer 
Facts 
& 
Figures 
2013. 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docum 
ent/acspc-036845.pdf. Accessed January 31, 2013. 
3. Greenwald, R. J., et al. (2005). "The B7 family revisited." Annu Rev Immunol 23: 515-548. 
4. Francisco, L. M., et al. (2010). "The PD-1 pathway in tolerance and autoimmunity." Immunol 
Rev 236: 219-242. 
5. Dudley, M. E., et al. (2005). "Adoptive cell transfer therapy following non-myeloablative but 
lymphodepleting chemotherapy for the  treatment of  patients  with  refractory metastatic 
melanoma." J Clin Oncol 23(10): 2346-2357. 
6. Hunder, N. N., et al. (2008). "Treatment of metastatic melanoma with autologous CD4+ T 
cells against NY-ESO-1." N Engl J Med 358(25): 2698-2703. 
7. Gao, Q., et al. (2009). "Overexpression of PD-L1 significantly associates with tumor 
aggressiveness and postoperative recurrence in human hepatocellular carcinoma." Clin Cancer 
Res 15(3): 971-979. 
8. Blank, C. and A. Mackensen (2007). "Contribution of the PD-L1/PD-1 pathway to T-cell 
exhaustion: an update on implications for chronic infections and tumor evasion." Cancer 
Immunol Immunother 56(5): 739-745. 
9. Iwai, Y., et al. (2002). "Involvement of PDL1on tumor cells in the escape from host immune 
system and tumor immunotherapy by PD-L1 blockade." Proc Natl Acad Sci USA 99(19): 12293- 
12297. 
10. Tsushima, F., et al. (2006). "Predominant expression of B7-H1 and its immunoregulatory 
roles in oral squamous cell carcinoma." Oral Oncol 42(3): 268-274. 
11. Korman, A., et al. (2007). "Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" 
PD-L1 and Synergistic  Effect of Anti-PD-1and Anti-CTLA-4." J Immunol 178 (abstr 48.37). 
12. Sznol, M., et al. (2010). "Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, 
BMS-936558/ONO-4538) in patients with advanced refractory malignancies." Proc Am Soc 
Clin Oncol 28: 3167-3175. 
13. Nomi, T., et al. (2007). "Clinical significance and therapeutic potential of the programmed 
death-1 ligand/programmed death-1 pathway in human pancreatic cancer." Clin Cancer Res 
13(7): 2151-2157. 
14. Cai, G., et al. (2004). "PD-1 ligands, negative regulators for activation of naive, memory, and 
recently activated human CD4+ T cells." Cell Immunol 230(2): 89-98. 
15. Hamid, O., et al. (2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in 
melanoma." N Engl J Med 369(2): 134-144. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 77
 
 
16. Rakhmilevich, A. L., et al. (1999). "Gene gun-mediated IL-12 gene therapy induces 
antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein 
therapy." J Immunother 22(2): 135-144. 
17. Lohr, F., et al. (2001). "Effective tumor therapy with  plasmid-encoded cytokines 
combined with in vivo electroporation." Cancer Res 61(8): 3281-3284. 
18. Lucas, M. L., et al. (2002). "IL-12 plasmid delivery by in vivo electroporation for the 
successful treatment of established subcutaneous B16.F10 melanoma." Mol Ther 5(6): 668- 
675. 
19. Lucas, M. L. and R. Heller (2003). "IL-12 gene therapy using an electrically mediated 
nonviral approach reduces metastatic growth of melanoma." DNA Cell Biol 22(12): 755-763. 
20. Titomirov, A.V., et al (1991). “In vivo electroporation and stable transformation of skin cells 
of newborn mice by plasmid DNA.” Biochim Biophys Acta 1088:131-134. 
21. Heller, L., et al. (2006). “Evaluation of Toxicity following Electrically Mediated Interleukin- 
12 Gene Delivery in a B16 Mouse Melanoma Model.” Clin Cancer Res 12:3177-3183. 
22. Daud, A. I., et al. (2008). "Phase I trial of interleukin-12 plasmid electroporation in patients 
with metastatic melanoma." J Clin Oncol 26(36): 5896-5903. 
23. OncoSec Medical, Inc. (2013). “OncoSec Medical Announces Positive Interim Data from 
Phase II Study of OMS-I100 in Metastatic Melanoma.” 
24. Agata, Y., et al. (1996). "Expression of the PD-1 antigen on the surface of stimulated mouse 
T and B lymphocytes." Int Immunol 8(5): 765-772. 
25. Vibhakar, R., et al. (1997). "Activation-induced expression of human programmed death-1 
gene in T-lymphocytes." Exp Cell Res 232(1): 25-28. 
26. Nishimura, H., et al. (2000). "Facilitation of beta selection and modification of positive 
selection in the thymus of PD-1-deficient mice." J Exp Med 191(5): 891-898. 
27. Tumeh personal communication 
28. Heinzerling, L., et al. (2002). "Tumor regression of human and murine melanoma after 
intratumoral injection of IL-12-encoding plasmid DNA in mice." Exp Dermatol 11(3): 232-240. 
29. Dong, H., et al. (2002). "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential 
mechanism of immune evasion." Nat Med 8: 793-800. 
30. Sharpe, A. H. and G. J. Freeman (2002). "The B7-CD28 superfamily." Nat Rev Immunol 2(2): 
116-126. 
31. Brown, J. A., et al. (2003). "Blockade of programmed death-1 ligands on dendritic cells 
enhances T cell activation and cytokine production." J Immunol 170(3): 1257-1266. 
32. Bohm, W., et al (1998). “T cell-mediated, IFN-gamma-facilitated rejection of murine B16 
melanomas.” J Immunol 161:897-908. 
33. Klein, O., et al. (2013). "BRAF inhibitor  activity in V600R metastatic melanoma-- 
response." Eur J Cancer 49(7): 1797-1798. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 78
 
 
34. Thomas, N. E., et al. (2013). "Tumor-infiltrating lymphocyte grade in primary melanomas is 
independently associated with melanoma-specific survival in the population-based genes, 
environment and melanoma study." J Clin Oncol 31(33): 4252-4259. 
35. Steding, C. E., et al. (2011). "The role of interleukin-12 on modulating myeloid-derived 
suppressor cells, increasing overall survival and reducing metastasis." Immunology 
133(2): 221-238. 
36. Kobayashi, M., et al. (1989). "Identification and purification of natural killer cell 
stimulatory factor  (NKSF),  a cytokine  with  multiple   biologic   effects   on  human 
lymphocytes." J Exp Med 170(3): 827-845. 
37. Brunda, M. J., et al. (1993). "Antitumor and antimetastatic activity of interleukin 12 against 
murine tumors." J Exp Med 178(4): 1223-1230. 
38. Gee, M. S., et al. (1999). "Hypoxia-mediated apoptosis from angiogenesis inhibition 
underlies tumor control by recombinant interleukin 12." Cancer Res 59(19): 4882-4889. 
39. Hofmann, G. A., et al. (1999). "Electroporation therapy: a new approach  for the 
treatment of head and neck cancer." IEEE Trans Biomed Eng 46(6): 752-759. 
40. Daud, A. I., et al.  (2014) “Antitumor activity of  the anti-PD-1 monoclonal antibody 
PEMBROLIZUMAB in melanoma (MEL): Correlation of tumor PD-L1 expression with outcome.” 
AACR Annual Meeting (abstr. CT104). 
41. Wolchok, JD, Hoos, A, O’Day S, et al., Guidelines for the Evaluation of Immune Therapy 
Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009 
Dec 1;15(23):7412-20. Epub 2009 Nov 24. 
42. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune 
resistance. Nature 515, 568-571, doi:10.1038/nature13954 (2014). 
43. Daud, AI., Loo, K., Pauli ML., et.al. Tumor Immune Profiling Predicts Response to Anti-PD-1 
Therapy in Human Melanoma. J Clin Invest. 2016 Sep 1; 126(9): 3447-52. doi: 
10.1172/JCI87324. Epub 2016 Aug 15. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 79
 
 
 
 
 
APPENDICES 
APPENDIX 1 PERFORMANCE STATUS CRITERIA 
 
 
 
ECOG Performance Status Scale 
Grade 
Descriptions 
0 
Normal activity 
Fully active, able to carry on all pre-disease performance without 
restriction 
 
1 
Symptoms, but ambulatory 
Restricted in physically strenuous activity, but ambulatory and able 
to carry out work of a light or sedentary nature (e.g., light 
housework, office work) 
2 
In bed < 50% of the time 
Ambulatory and capable of all self-care, but unable to carry out 
any work activities 
Up and about more than 50% of waking hours 
 
3 
 
In bed > 50% of the time 
Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours 
 
4 
100% bedridden 
Completely disabled 
Cannot carry on any self-care 
Totally confined to bed or chair 
5 
Dead 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 80
 
 
APPENDIX 2 DATA AND SAFETY MONITORING PLAN FOR MULTICENTER INSTITUTIONAL 
STUDY 
(PHASE 2 OR 3 INSTITUTIONAL STUDY) 
 
The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring 
Committee (DSMC) is responsible for monitoring data quality and subject safety for all HDFCCC 
institutional clinical studies. A summary of DSMC activities for this study includes: 
 
 
• 
Review of suspected adverse reactions considered “serious” 
 
 
Monitoring and Reporting Guidelines 
The UCSF Coordinating Center provides administration, data management, and organizational 
support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating 
Center will also coordinate quarterly conference calls with the participating sites to communicate the 
review of adverse events, safety data, and other study matters. 
 
 
The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study 
Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at 
all participating sites. The Study Chair will conduct continuous review of data and subject safety and 
discuss each subject’s treatment at monthly UCSF Site Committee meetings. The discussions are 
documented in the UCSF Site Committee meeting minutes. 
Multicenter communication 
The UCSF Coordinating Center provides administration, data management, and organizational 
support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating 
Center will also coordinate, at minimum, monthly conference calls with the participating sites at the 
completion of each cohort or more frequently as needed to discuss risk assessment. The following 
issues will be discussed as appropriate: 
• 
Enrollment information 
• 
Adverse events (i.e. new adverse events and updates on unresolved adverse events and new 
safety information) 
• 
Protocol violations 
• 
Other issues affecting the conduct of the study 
Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, 
as well as the participating sites. The DSMC will be responsible for monitoring all data entered in 
OnCore® at the UCSF Coordinating Center and the participating sites. The data (i.e. copies of source 
documents) from the participating sites will be sent electronically or faxed over to the UCSF 
Coordinating Center prior to the monitoring visits in order for the DSMC to monitor the participating 
site’s compliance with the protocol, patient safety, and to verify data entry. 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 81
 
 
 
 
Adverse Event Review and Monitoring 
Adverse Event Monitoring 
All Grade 3-5 Adverse Events, whether or not unexpected, and whether or not considered to be 
associated with the use of study drug, will be entered into OnCore®, UCSF’s Clinical Trial Management 
System. 
All Grade 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF 
Site Committee meetings. All clinically significant adverse events must be reported to the UCSF 
Coordinating Center by the participating sites within 10 business days of becoming aware of the event 
or during the next scheduled quarterly conference call, whichever is sooner. The UCSF Site Committee 
will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of 
the adverse event to the administration of the study drug(s) from the UCSF Coordinating Center and 
the participating sites. 
In addition, all suspected adverse reactions considered “serious” must be entered in OnCore® and 
reported to the UCSF Coordinating Center within 1 business day. The suspected adverse reactions 
considered “serious” will be reviewed and monitored by the  Data  and  Safety Monitoring Committee 
on an ongoing basis and discussed at the DSMC meeting, which take place every six (6) weeks. 
If a death occurs during the treatment phase of the study or within 30 days after the last 
administration of the study drug(s) and is determined to be related either to the investigational drug 
or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned 
designee must be notified within 1 business day from the participating site(s) and the Study Chair 
must then notify the DSMC Chair or qualified alternate within 1 business day of this notification. The 
contact may be by phone or e-mail. 
 
 
Increase in Adverse Event Rates 
If an increase in the frequency  of Grade 3 or 4 adverse events (above the rate reported in the 
Investigator Brochure or package insert), the Study Chair at the UCSF Coordinating Center is 
responsible for notifying the DSMC at the time the increased rate is identified. The report will indicate 
if the incidence of adverse events observed in the study is above the range stated in the Investigator 
Brochure or package insert. 
If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair 
and DSMC Manager must be notified within 1 business day via e-mail. The DSMC must receive a formal 
letter within 10 business days and the CHR must be notified. 
Data and Safety Monitoring Committee Contacts: 
 
DSMC Chair: 
Alan Venook, MD 
DSMC Monitors 
Phone: 
Email: 
Address: 
 
 
 
 
UCSF Helen Diller Family Comprehensive 
Cancer Center 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 82
 
 
* DSMP approved by NCI 09/February2012 
 
 
APPENDIX 3 UCSF POLICY/PROCEDURE FOR REQUIRED 
REGULATORY DOCUMENTS FOR A UCSF MULTICENTER 
INVESTIGATOR-INITIATED ONCOLOGY CLINICAL TRIALS WITH AN 
INVESTIGATOR HELD INVESTIGATIONAL NEW DRUG (IND) 
 
Purpose 
This policy defines the required Regulatory Documents for Single Site and Multicenter Investigator 
Initiated Oncology Clinical Trials at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) 
where the Principal Investigator (PI) holds the IND. 
 
 
Background 
The International Conference on Harmonization (ICH) Good Clinical Practices (GCP) Guidelines define 
Essential Regulatory Documents as  those documents which individually and collectively permit 
evaluation of the conduct of a trial and the quality of data produced. These documents serve to 
demonstrate compliance with standards of GCP and with all applicable regulatory requirements. 
Filing essential documents in a timely manner can greatly assist in the successful management of a 
clinical trial. 
The Regulatory Documents will consist of electronic files in both iMedRIS and OnCore®, as well as 
paper files in the Regulatory Binders for both the Coordinating Site and the Participating Site(s) in the 
HDFCCC Investigator Initiated Oncology Clinical Trials. 
 
 
Procedures 
1. 
HDFCCC Essential Regulatory Documents 
Documents Filed in iMedRIS: 
• 
CHR approvals for initial submission of application, all modifications, and continuing annual 
renewals 
• 
Current and prior approved protocol versions with signed protocol signature page(s) 
• 
Committee for Human Research (CHR) approval letters and Informed Consent Form(s) (ICF) 
• 
Current and prior versions of the Investigator Brochure (IB). 
• 
Serious Adverse Event Reporting 
• 
Protocol Violations and Single Patient Exception (SPE) Reports to CHR with supporting fax 
documentation 
Documents Filed in OnCore®: 
 
 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 83
 
 
• 
Package Insert (if the study drug is commercial) or Investigator Brochure 
• 
Protocol Review Committee (PRC) approved protocols, protocol amendments and 
Summary of Changes (SOC) 
• 
Patient handouts 
• 
Screening/enrollment log 
• 
Data and Safety Monitoring Committee (DSMC) monitoring reports 
• 
OnCore® Case Report Form (CRF) completion manual 
Documents Filed in Regulatory Binder: 
• Completed Food and Drug Administration (FDA) 1572 document with  Principal 
Investigator’s signature 
• 
For all Principal Investigators and Sub-Investigators listed on the FDA 1572, will need 
Financial Disclosure Forms, CVs, MD Licenses, Drug Enforcement Agency (DEA) Licenses, and 
Staff Training Documents (i.e. Collaborative Institute Training Initiative (CITI), etc.) 
• 
Site Initiation Visit (SIV) minutes and correspondence with participating site(s). 
• 
As applicable, approvals for Biosafety Committee, Radiation Committee, and Infusion Center 
• 
Serious Adverse Event (SAE) reports to CHR, Merck and OncoSec Medical and 
• 
MedWatch reporting to FDA, Merck and OncoSec Medical and 
• 
Delegation of Authority Form 
• 
Drug Destruction Standard Operating Procedure (SOP) 
• For all  laboratories  listed on the  FDA 1572,  will need CLIA certifications, CAP 
certifications, lab licenses, CVs of Lab Directors, and laboratory reference ranges 
2. Additional Essential Documents for Multicenter Trials for the Coordinating Center (filed in 
Regulatory Binder or OnCore) 
• 
Institutional Review Board (IRB) approval letters, IRB roster, Informed Consent Form (ICF), 
and Health Insurance Portability and Accountability Act (HIPAA) Consent Form for the 
Participating Site(s) 
• 
For all Principal Investigators and Sub-Investigators listed on the 1572 at the Participating 
Site(s) – Financial Disclosure Forms, CVs, MD Licenses, and Staff Training documents (i.e. 
Collaborative Institute Training Initiative (CITI), etc.) (for Investigational New Drug 
Application 
• 
Site Initiation Visit (SIV) minutes and correspondence with Participating Site(s). 
• 
As applicable, approvals for Biosafety Committee, Radiation Committee, and Infusion Center 
for the Participating Site(s) 
• 
Protocol Violations and Single Patient Exception (SPE) reports to IRB with supporting fax 
documentation for Participating Site(s) 
• 
Drug Destruction Standard Operating Procedure (SOP) for the Participating Site(s) 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 84
 
 
• Data and Safety Monitoring Committee (DSMC) monitoring reports for the Participating Site(s) 
• 
For all laboratories listed on FDA 1572, will need CLIA certifications, CAP certifications, lab 
licenses, CVs of Lab Directors, and laboratory reference ranges for the Participating Site(s) 
• 
Copy of the Data and Safety Monitoring Plan (DSMP) Monitoring Plan for all participating 
site(s) in Multicenter studies or Contract Research Organization (CRO) Monitoring Plan (if an 
outside CRO is used for the study) 
• 
Serious Adverse Event (SAE) forms submitted to both the IRB and the Sponsor-Principal 
Investigator for the Participating Site(s) 
 
 
 
 
27 April 2012 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 85
 
 
Required Regulatory Documents for Sub-sites Participating in a UCSF 
Investigator Initiated Multicenter Trial (Checklist) 
Directions: 
1) Fax the documents listed below to the UCSF Coordinating center at 415-514-6955 or 
2) Scan the documents and upload to OnCore® and create a Note to File for the on-site 
Regulatory binder to indicate where these documents may be found 
 
1572 
<0000> PI and Sub investigators: 
<0000> 
CV and  Medical license 
<0000> 
Financial disclosure form 
<0000> 
NIH or CITI human subject protection training certification 
<0000> Laboratories 
<0000> 
CLIA and CAP 
<0000> 
CV of Lab Director and Lab Licenses 
Laboratory reference ranges 
Local Institutional Review Board 
<0000> IRB Approval letter 
<0000> Reviewed/Approved documents 
<0000> 
Protocol version date:   
 
<0000> 
Informed consent version date:   
 
<0000> 
Investigator Brochure version date:   
 
<0000> 
HIPAA 
<0000> Current IRB Roster 


Version date: 10-12-2017
Protocol CC#:15852
IT pIL-12 EP and antiPD-1
Page 73
 
 
Other 
 
 
 
 
<0000> Delegation of Authority Log 
<0000> Include  NIH or  CITI  human subject  protection training  certificates or GCP training 
certification 
<0000> Pharmacy 
<0000> 
Drug destruction SOP and Policy 
<0000> Protocol signature page 
<0000> Executed sub contract 
 
 
27.apr.2012